Cécile Couchoud  (REIN Registry, France)


Angel de Francisco  (University of Cantabria, Spain)

In the Breakout Group 4: Nephrotoxins (Contrast) we need to discuss cancer patient as a risk factor and ESUR 10 guidelines which are based in weak recommendations score. Cancer Patients as a Risk Factor: Why does the cancer patient have a high risk factor for Acute Renal Lesion after contrast and should not be excluded?

1. The cancer patient has a higher risk of AKI

2. Frequent CKD in the oncological patient, especially in those in which cancer is more frequent with ages> 65 years.

3. Frequent associations with Nephrotoxic treatments 50% of anti-cancer drugs are predominantly excreted in the urine and 80% of patients receive drugs potentially nephrotoxic and / or for which the dose must be adjusted The presence of pre-existing renal insufficiency may limit the use of otherwise active regimens that may be curative.
• Janus N, Launay-Vacher V, Byloos E, y cols. Cancer and renal insufficiency results of the BIRMA study. Br J Cancer 103: 1815–1821, 2010  In patients with exposure to contrast media one week before the administration of cisplatin, the risk of AKI-CP was significantly higher than in patients without such exposure

4. Frequency of studies with contrast media in cancer patients. The recommendations for the staging and monitoring of cancer treatments require the performance of studies with iodinated contrast very frequently. In colorectal cancer, CT with a thoraco-abdominal contrast is recommended every 3-6 months for two years and then every 6-12 months for 5 years In lung cancer for diagnosis and staging, chest CT with contrast (and PET with CT or brain MRI) is recommended, which should be performed annually
• ESUR 10 We should discuss many recommendations without evidence
It is postulated that many IA administrations are similar to the IV for the kidney because the contrast arrives diluted. In our opinion:
- No evidence is provided to justify the differentiation of primary or secondary renal exposure (theoretical assumption)
- Does not consider factors related to the patient, their comorbidity and the type of procedure.
- It contradicts and omits the high evidence of the risk of AKI in contrast exposure by the intra-arterial coronary route, which reflects the guidelines in cardiology.
- Does not consider that this risk can also be transferred to patients undergoing CT with contrast, as has been demonstrated in patients with risk factors other than renal.
- Lowering of renal risk omitting non-renal risk factors:
- GFR <45ml / min / 1.73m² in intra-arterial administration with direct renal exposure or in patients in ICU.
- GFR <30ml / min / 1.73m² in intra-arterial or iv administration with secondary renal exposure.

José António Lopes  (Centro Hospitalar Lisboa, Portugal)

In fact, the AKI definition, the mechanistic pathways, the management and knowledge of impact on prognosis have all evolved in the current decade and justify this conference.

Greg Knoll  (The Ottawa Hospital, Canada)

Is post-transplant delayed graft function in scope? Many of the issues being discussed in the non-transplant setting (e.g. nomenclature, diagnosis, fluid management etc) are also critical, unresolved issues in the transplant setting. Thanks.

George Bakris  (University of Chicago, USA)

This looks reasonable. However, this guideline has caused a great deal of confusion with the general medical literature and definitions have been inter mixed between 50% increase in creatinine and 0.3 which restricted to hospitalized heart failure patients-BIG mistake to intermingle these even the original author of the 2000 paper Krumholtz has said this is probably not correct. Moreover, people are using the 0.3 mg change in creatinine to signal AKI in the outpatient setting. I don’t care how clear you are, as a guideline writer I think you need to be honest with the data and restrict this to heart failure. Moreover, I have attached some recent papers (included at the end of this document) that clearly are NOT AKI but hemodynamic changes that are being called AKI-This confusion needs to end and only you can help.

Best Wishes, George
Peter McCullough  (Baylor University Medical Center, USA)

1) Insert a section on worsened renal function in the setting of acute heart failure with a vetting of whether this is AKI or azotemia related to delayed plasma refill

2) Insert mention of Iodine-125–Tagged Albumin in acute heart failure and the studies conducted to date as an aid in management

3) Insert a section on AKI and the progression of CKD

4) Insert mention of hyperkalemia as a complication of AKI and provide information on its epidemiology, prevention, and management

Andrew Crannage  (St. Louis College of Pharmacy, USA)

The scope appears appropriate, would ask that emphasis be placed on prevention as still an area of need and has been confirmed in recent studies.

Rinaldo Bellomo  (Austin Hospital, Australia)

Breakout group 1: topic 3: discuss role of follow-up to determine the best time to measure recovery. Should it be at 3 months? Later?

Breakout group 2: discuss the combination of clinical models with biomarkers

Breakout group 3: discuss the effect of fluid bolus on renal function and what technology can be used to monitor fluid removal

Breakout group 4: discuss ACE inhibitors and the timing of their re-start after AKI

Breakout group 5: discuss the criteria for cessation of RRT
Mark Murphy  (Irish Kidney Association (IKA), Ireland)

The IKA is a kidney Patient Association, and is made up of patients with a chronic condition. The AKI patients don’t end up in our type of organisation unless their acute condition turns into a chronic condition. So we don’t have much to offer on this topic.

Regards,
Mark Murphy

Thomas Golper  (Vanderbilt University Medical Center, USA)

In the US it matters greatly whether terms like AKI versus ATN are used. There should be included criteria for the use of the terms. For example, ATN is very likely in many critically ill pts who are properly resuscitated and renal dysfunction worsens after several days. Yet AKI, while true, affects coding and payment much differently for the hospital.

Cibele Rodrigues  (Pontifícia Universidade Católica de São Paulo, Brazil)

1- Agree with the scope and I want to make a suggestion. Acute kidney injury is common in kidney transplant recipients and there's no breakout group about this topic. It's a challenging work. Certain features and risk factors are specific to kidney allografts like rejection, drug toxicity, recurrence of kidney disease, infections, urinary tract obstruction, vascular thrombosis, and so on.

2- We all know that most physicians alter therapy depending on changes in serum creatinine, and this often represents delayed intervention, but that's what is possible in our country (and many others). Various AKI biomarkers have been discovered and validated but they are not available in the clinical setting.

Kianoush Kashani  (Mayo Clinic, USA)

Group 2: - Clinical models:
- Computational vs. bedside calculated
- Discrete vs continuous - Diagnosis and monitoring: It may be as of interest to at least partly focus on monitoring measures that are kidney focused not CV hemodynamic variables: e.g., intraabdominal pressures, contrast-enhanced US, non-invasive kidney elastography, kidney
perfusion pressure, continuous GFR monitoring, urinary sodium, ammonium, oxygen monitoring, microcirculation, etc. - "Which patients should be followed up?" could be expanded to: "who, where, how, what should be monitored after AKI?"

Group 4: one potentially important topic would be the relationship between chemotherapies and AKI (particularly new biologicals). Would it be possible to dedicate a question to Onco-AKI?

Group 5: Risk prediction for the need to initiate RRT may be a good addition

Andrew Davenport  (University College London, UK)

Dear John, there are problems with definition

1. descriptive based on changes serum creatinine/urine - we need to consider underlying etiology
2. same % change in serum creatinine does not result in equivalent injury or chance of recovery or later risk of end stage kidney failure
3. need to review treatment options PD vs IHD/F vs CRRT - as we have have now learned how to deliver more efficient PD
4. need to consider effects of RRT and drug clearances - particularly antibiotics

Clarissa Havel  (RPh-on-the-go, USA)

Timely review and good questions of aki, mirrors the ACCP board re-certification of BCPS for pharmacists. The KDIGO notes on the Acute Kidney Injury are consistent with the pharmacotherapy for Board Re-certification.

Sincerely,
Clarissa Havel, PharmD, BCPS

Fan Fan Hou  (Nanfang Hospital, China)

Suggestion for some additional topics:

Breakout Group 1: Diagnostic Criteria
1. What is the appropriate diagnostic criteria for pediatric AKI? Is it possible to incorporate reference change value of serum creatinine into the diagnosis of pediatric AKI?
2. How to diagnose acute-on-chronic kidney injury?

Breakout Group 2: Prognostication
1. What is the impact of AKI on long-term mortality?
2. How to identify patients who are at high risk of AKI to CKD progression? Any available biomarkers?

Breakout Group 4: Nephrotoxins
Any newly found nephrotoxic drugs (PPIs/H2RAs)?

Breakout Group 5: Renal Replacement Therapy
What criteria should be used to stop RRT?

Mehmet Sukru Sever  (Istanbul School of Medicine, Turkey)

Many thanks in advance for this excellent work. Just 3 suggestions; can you also comment on:
1. Indications /non-indications for biopsy
2. Fluid policy during resolution of AKI
3. AKI in transplant setting.

Ken Say  (U.S. Public Health Service, Indian Health Service, USA)

Regarding nephrotoxins: Is there enough evidence to support stronger warnings/labeling for OTC and RX NSAIDs and AKI risk? Risk is not well defined or articulated in the recommended patient information from the FDA. Is the risk significant enough to merit more focus on patient education/clinical intervention especially during times of acute illness (dehydration, volume depletion) and/or in combination with other medications such as ACEI/ARBs, diuretics? See link to NHS UK campaign for sick day guidance. Agree with risk statements against stopping diuretics and anti-hypertensives, but is evidence sufficient for stronger recommendations to stop/limit/avoid NSAIDs during acute illness? https://www.thinkkidneys.nhs.uk/aki/wp-content/uploads/sites/2/2018/01/Think-Kidneys-Sick-Day-Guidance-2018.pdf
Rolando Claure-Del Granado  (Universidad Mayor de San Simon, Bolivia)

Is sufficient evidence now available to warrant a change in the definitions/classification/staging system for AKI? I think yes it is, I would recommend that subclinical AKI should be addeed to the new definitions and urinary microscopy should be considered for this nomenclature. How should existing (or new) definitions of AKI be implemented at the bedside, in research? Using back calculation of MDRD should be included for determining a baseline sCr in every patient. What are the roles for risk-stratification of patients for AKI? A consideration should be made on adaptations to the RAI for adult population (I have some research on this area) How should patients be followed after AKI? Recommendations should be made about a follow up plan, I think after 7 days, at day 30 and day 90. In light of current evidence what can be recommended for prevention and management of contrast-associated AKI? There is still a population with CKD at higher stages like 4 that would benefit from profilaxis strategies, recommendation should be made about individualized risk assessment and type of profilaxis that should be used. A risk score should be proposed not only for patients Post-PCI (the only one available) Is there sufficient evidence to classify potential nephrotoxins in a clinical useful way? You must include herbs as potential toxins!!!

Hassan Shora  (Port-Said University, Egypt)

The conference scope is comprehensive. We need to add important area of coverage such as dilemma in management of acute cardiorenal syndrome, implications of systems and precision nephrology for AKI management including complex deep neural networks analysis and clinical decision support system for AKI. The controversial use of myoglobin as a biomarker of AKI in rhabdomyolysis.

Ikechi Okpechi  (University of Cape Town, South Africa)

Dear KDIGO,
The scope and contents of this controversies conference is broad and detailed. I have no further additions to make.
Kind regards,
Ike
Hassan Aleid  (King Faisal Specialist Hospital, Saudi Arabia)

1. Wish to see a chapter on AKI-transplant
2. Potential promising therapy

Eisei Noiri  (University of Tokyo, Japan)

Knowledge Gaps: Is this the timing to change creatinine and urine output definition to further (depending on clinical scenario, etc)? The difference of therapeutic considerations to AKI stage (ex. Stage 1 vs 2 and 3) have to be stated as a scope of care bundle. Renal angina index (RAI) was recently proved the efficacy to detect persistent AKI in pediatric ICU cohort using concise combination of creatinine-increase and clinical condition. However, use of RAI in adult ICU is not well established. HSCT in above mentioned RAI often cause AKI in adult but such clinical data is not well accumulated, though knowing the occurrence of AKI after HSCT on survival. This will be partly because of the missing link between hematologist and nephrologist or intensivist. Potential monitoring device for longer creatinine clearance (functional) or biomarker (injury) monitoring should be stated in the manuscript as future perspective. The adsorption modality to sepsis including septic AKI such as PMX-DHP and Cytosorb should be mentioned based on the current clinical evidence and perspective. Biomarkers approved for clinical use (NephroCheck, NGAL, L-FABP, Cystatin C, NAG, etc) should be discussed for their characteristics in terms of strong and weak points for proper use and interpretation. The definition of radiocontrast media induced AKI is still the same as before in cardiology area. AKI evaluation approach to newly up-coming treatment such as TAVI and TAVR in cardiology, hematological new drugs (...mibs, immune checkpoint inhibitors), CAR-T should be discussed and suchlike.

Paul Stevens  (East Kent Hospitals University NHS Foundation Trust, UK)

Breakout Group 1: Question 1. Metabolomic profiling is just starting to take off in assessment of estimated GFR and may have advantages in areas where eGFR based on creatinine is unreliable, worth considering for AKI too

Breakout Group 3: Question 3. Might ask one of these questions a slightly different way ie what are the predictors of CKD in patients recovered from AKI?
Breakout Group 4: Question 2. Criteria for classification could also be vascular, glomerular, tubular - for example certain nephrotoxins are vasoactive, some may cause thrombotic microangiopathy, others are tubulotoxic or lead to interstitial nephritis etc.

Finally, don’t forget about AKI prevention/early identification in primary care.

Charles Tomson  (Retired nephrologist, UK)

I strongly encourage KDIGO to differentiate between true 'nephrotoxins' and drugs that may affect glomerular haemodynamics and/or systemic BP and thus have some effect on GFR, such as ACEI and ARB; these drugs may actually protect against tubular injury. The question of whether or not to continue or discontinue these drugs during sepsis, hypotension, and other precipitants of AKI is open, and should be a topic for review. Calling them 'nephrotoxic' presupposes that they should be stopped during AKI. The previous guideline failed to give clear guidance on this. Even if the evidence base is limited on when/whether to continue these drugs (for instance, depending on the indication - HFrEF vs proteinuric kidney disease vs 'standard' early onset hypertension) clear guidance should be given on whether/when they should be discontinued, and even more importantly, when they should be restarted.

Eugen Mota  (University of Medicine and Pharmacy Craiova, Romania)

AKI is an important clinical syndrome associated with poor clinical outcomes for hospitalised patients. The current diagnostic approach of AKI is based on an acute decrease of GFR, as reflected by an acute rise in sCr levels and/or a decline in urine output over a given time interval. Recently several biomarkers have been proposed for the diagnosis of AKI and these are in various stages of development and validation. Nevertheless, it is not clear, if a single or multiple biomarker approach is necessary to diagnose the complicated and multifactorial aspects of AKI. However, in addition to the analytical difficulties associated with each specific biomarker, there is also an issue concerning the appropriate reference point, and more specifically about using sCr as the standard, for the clinical evaluation of these biomarkers. It is known that sCr is insensitive to acute changes of renal function and levels can vary widely with age, gender, muscle mass, diet, medications and hydration status. Moreover it is not a direct marker of tubular damage, but rather a marker of GFR, and substantial increases in sCr can be observed in renal hypo-perfusion even when the kidneys are structurally intact, resulting in pre-renal azotaemia. For these reasons sCr is considered an ‘imperfect “gold standard”’ for the diagnosis of AKI. Another issue with sCr is that in most clinical situations its true baseline value
is not known, which makes the evaluation of patients very difficult. Moreover, given the phenotypic variability of AKI (different clinical phenotypes with distinct underlying pathophysiologies), it is not clear. Essentially AKI is a term used to describe the clinical syndrome that occurs when renal function is acutely decreased to a point that the body accumulates waste products and becomes unable to maintain electrolyte, acid-base and water balance. The pathophysiology of AKI is multifactorial and complex. The most common cause of AKI is ischaemia, which can occur for a number of reasons. AKI is also very common in the setting of sepsis. In sepsis the circulation is hyperdynamic and blood flow is altered, albeit not necessarily in the ischaemic range, and GFR drops rapidly. The pathophysiology of septic-AKI is very complex and involves inflammation, oxidative stress microvascular dysfunction and amplification of injury via secretion of cytokines by tubular cells. Kidney and cardiac disease are not only common but often coexist. Both acute and chronic cardiac disease can contribute directly to acute and/or chronic worsening of renal function and vice versa. The term cardiorenal syndrome (CRS) is often used to describe this condition and represents an important model for the exploration of the pathophysiology of cardiac and renal dysfunction. Recently a consensus definition/classification scheme has been proposed for the CRS. According to this definition, five subtypes of the CRS exist. Each subtype’s etymology reflects the primary and secondary pathology, cardiac and renal as well as dysfunction secondary to systemic disease. It is important to distinguish hepatic dysfunction as a result of AKI as distinct from the well-recognised hepatorenal syndrome (HRS). Liver injury often correlates with severity of kidney injury. Ischaemic AKI induces oxidative stress and promotes inflammation apoptosis and tissue damage to hepatocytes. On the other hand the concept of HRS is very well recognised; it is a reversible functional renal impairment that occurs in patients with advanced liver cirrhosis or in patients with fulminant hepatic failure. It is characterised by a marked decrease in GFR and renal blood flow in the absence of other causes of renal injury. HRS is not uncommon and occurs in approximately 40% of patients with advanced cirrhosis. Maintenance of volume homeostasis and correction of biochemical abnormalities remain the primary goals of AKI treatment. Dietary changes are an important facet of AKI treatment. Restriction of salt and fluid becomes crucial in the management of oliguric renal failure, in which the kidneys do not adequately excrete either toxins or fluids. Pharmacologic treatment of AKI has been attempted on an empiric basis, with varying success rates. Considerable advances have been made in refining the definition of this syndrome and in the elucidation of the underlying pathophysiologic mechanisms of the different clinical phenotypes. It is obvious that all clinical phenotypes of AKI cannot fit into a single pathophysiologic pathway. AKI facilitates organ cross-talk and distant organ injury. These innovations will aid in the design of epidemiologic studies and randomised trials of preventive and therapeutic interventions.
Josee Bouchard  (University of Montreal, Canada)

Dear Drs Kellum and Ostermann,
Please find comments and suggestions below.

Breakout Group 1: Nomenclature & Diagnostic Criteria
-would suggest including discussion on issues with the diagnosis of AKI with CKD stage 4/5
-for the best way to define renal recovery, what would be the optimal period of time, and whether it would be during or after hospitalization if not community-acquired AKI

Breakout Group 2: Risk Stratification
-for "How should patients be followed after AKI?" comments on the role of nuclear medicine exams to measure GFR in some populations

Breakout Group 4: Nephrotoxins
1. "what can be recommended for prevention and management of contrast-associated AKI?"
need to/how to optimize fluid administration: i.e. amount of fluid to be administered/benefit of targeting a specific LVEDP value?

Breakout Group 5: Renal Replacement Therapy
-issues with therapeutic trials with RRT and other therapeutic agents for prevention and treatment of AKI

Wish you both a successful and Happy New Year,
Sincerely,
Josee Bouchard

Norbert Lameire  (University Hospital Gent, Belgium)

General remarks:
The guideline should not forget that it should address not only AKI in the critically ill (although this is of course very important) but also the probably more frequent “community AKI”. In addition, the KDIGO guidelines are global and not only trying to provide guidance to the high tech and sophisticated clinical hospital possibilities in high income countries. The clear distinction definition between AKD and AKI should be discussed. As far as can be derived from the ADQI definitions (see Chawla et al Nature Reviews Nephrology) is AKD an “a posteriori” diagnosis; i.e. an “extended AKI”; what is the impact of AKID on epidemiology and coding of
AKI? How to apply the present and future KDIGO AKI definition to severe acute glomerular, interstitial and vascular kidney diseases? “Transient AKI” is formulated as opposite of “recurrent” AKI. We believe that the dichotomy between “transient” and “intrinsic” AKI is more important. In the section on biomarkers the necessity of adequate and objective studies on the “added value” of biomarkers vis à vis the traditional diagnostic approach to AKI should be discussed. What is the significance of the diagnosis of “subclinical” AKI since it is a concept that is based on “inadequate” measurement and interpretation of glomerular filtration.

Additional remarks:
- Breakout group 1: 1h: definition of community vs hospital acquired AKI; hospital acquired AKI= ICU + non ICU? should be regarded as separate entities; community acquired: not hospitalized or AKI before 48h after hospitalization?, AKI on admission? 2b: urinary output in ml/kg/h but what weight should be used? ideal weight (in fluid overloaded ICU patients), actual weight? 3: remaining question: at what time point should AKI recovery be assessed?

- Breakout group 2: who should do the follow-up of post AKI patient? Post AKI clinic? General nephrology department?

- Breakout group 3: how to define and clinical diagnosis of fluid overload?

- Breakout group 4: Role for measuring peak and trough serum levels of certain potentially nephrotoxic drugs? Is there a role of biomarkers to early detection of nephrotoxicity?

- Breakout group 5: Dosing of antibiotics across different RRT modalities It can be suggested that the KDIGO AKI guideline should include separate sections on Cardio renal, hepato-renal, oncology AKI and AKI in pregnancy.

These suggestions are formulated after discussion of the topic in the renal division of the Ghent University Hospital between Norbert Lameire, Raymond Vanholder, Wim Van Biesen and Jill Vanmassenhove.

**Jose Perez** *(Baylor College of Medicine, USA)*

Nomenclature & Diagnostic Criteria
- With the increasing evidence of AKI in the ICU settings, prompt diagnosis and prompt interventions to minimize risk of further kidney injury is of the utmost importance. Having appropriate nomenclature for AKI/AKD/CKD/NKD is appropriate for research and for bedside
care. Often times in our clinical practice at our academic institution, nephrology is consulted late in the care of these critically ill patients where we are often limited in our options for the care of these patients. Serum Creatinine is and imperfect marker for detecting severe AKI. Prompt diagnosis is of the utmost importance in the care of these patients. Education amongst physicians, not only nephrologist, but Critical Care, Medicine, Surgery etc will promptly identify these patients and allow for appropriate intervention.

Risk Stratification
- Patients and their families want to know what type of prognosis they have regarding their kidney health. Many patients will need long term follow up, however when a kidney injury occurs, having solid data would be beneficial in helping guide the care of these patients. Those patients in poverty-stricken areas may also be at high risk of ongoing kidney injury given their socioeconomic risk factors. Having an understanding of what environmental conditions play in the recovery of kidney injury will also be beneficial.

Fluid Management
- Fluid management plays a crucial role in the care of patients with kidney injury. Having an understanding of appropriate ways of monitoring fluid levels within the patient is an area that is often debated amongst the care providers from different specialties (cardiology vs critical care vs nephrology). Should alkaline fluid also be a question regarding the composition of IVF preparation?

Nephrotoxins
- Contrast associated AKI remains debatable, with recent large meta-analysis demonstrating no increased risk of AKI in those pts with and without contrast imagining. However, many clinicians still fear the risk associated with contrast in those patients with underlying CKD. Having a risk classification for nephrotoxins is beneficial (similar to those risk classifications for medications given during pregnancy). However, there are too many variables in the toxicity of potential nephrotoxins such as age and body size of patient, underlying risk factors, underlying kidney disease.

Renal Replacement Therapy
- RRT initiation remains a debatable topic amongst nephrologists and colleagues in other subspecialties. The timing and modality of RRT also plays a large role in the care of those patients with AKI. In our clinical practice, we have multiple hospitals including a public county-based hospital and multiple private hospital. Within these institutions, there are significant differences in resources including access to CRRT vs other dialysis modalities. Within these institutions, our practice differs in that within the private hospital with easy access to
modalities and nursing, physicians are more likely to initiate CRRT when compared to patients within the county system where nursing and dialysis machines may be more limited. Late start dialysis is the general practice within the county where as in our private hospitals, we generally initiate earlier.

Yusuke Tsukamoto  (Itabashi Chuo Medical Center, Japan)

1. In most of clinical fields (at least in Japan), etiology of AKI is still classified into pre-renal, renal parenchymal and post-renal. And FENa and FEUN are often misused. I would suggest to validate this classification measure. Is this still useful?

2. In polyuric phase of AKI, it is not easy to decide the timing of cessation of fluid replacement. What is the good indicator to diagnose recovery of concentration disorder during polyuria?

Andrew Levey  (Tufts Medical Center, USA)

I'm pleased to see that there will be continuing discussion regarding nomenclature regarding the overlap of AKI and AKD and their continuum with CKD. I'd also like the group to consider re-naming RRT to be KRT, to be consistent with other English-language preferred kidney disease nomenclature.

Marty Lefkowitz  (Novartis Pharmaceuticals Corporation)

The program would benefit by the inclusion of a section on clinical trials (inclusion criteria, endpoints, consideration for trials in different types of AKI (eg, CIN, cardiac surgery, sepsis) for the prevention / treatment of AKI.

Maurizio Gallieni  (University of Milano, Italy)

I have a strong interest in the topics of breakout group 4 on Nephrotoxins. During the recent KDIGO Controversies Conference on Onconephrology, the nephrotoxic effects of cancer treatment, as well as the issue of repeated contrast media use during cancer follow-up, have been debated and there is a need for more research and guidance on AKI in this fragile patient population. The presence in breakout group 4 of an expert in onconephrology could be of relevance. Again in breakout group 4, question 1 on contrast media should be expanded with a
re-evaluation of the role of iso-osmolar versus low-osmolar CM, which was addressed in the 2012 AKI KDIGO guidelines. The single and cumulative dose of CM in determining CM associated AKI should be addressed. A question on different approaches in intra-arterial versus intravenous administration of CM could be another important issue with available evidence (they have different effects). The main unanswered questions are, in my view, those related to the use of CM in patients with advanced CKD (Stage 4, 5, and 5D), because the lower observed toxicity with IV administration of CM could allow a more open use of radiological exams which are now denied (maybe inappropriately) while, on the other hand, it could turn out that CM associated kidney damage is indeed a relevant issue in advanced CKD patient and we should still apply measures which proved ineffective in patients with higher GFR. The issue of preservation of residual renal function is also quite relevant, in relation to the need for CM radiological exams at the beginning of dialysis and for the evaluation of idoneity to a kidney transplant. A simple question that could be added is the following: which is the best approach to the use of contrast media in patients with advanced CKD. Finally, the issue of renal replacement therapy in the critically ill cancer patient is an issue worth discussing in breakout group 5.

**Lynne Sykes**  *(Salford Royal Foundation Trust, UK)*

Dear Colleagues,

Please let me bring to your attention the following work on acute kidney injury that we have completed and published from Salford Royal NHS Foundation Trust. The first “A narrative review of the impact of interventions in acute kidney injury” outlines the recent evidence on interventions and their impact on AKI mortality and critical care admission. The second “Reducing acute kidney injury incidence and progression in a large teaching hospital” details our own highly effective quality improvement project in Salford Royal NHS Foundation Trust, the generalisability and the challenges faced.


“The NCEPOD of 2009 has been a great motivator by creating improved public awareness of AKI, increasing its profile in the NHS, and by provoking the introduction of financial incentives. This narrative review supports the growing body of evidence that grouped interventions can create an impact on the progression and severity of, and mortality from, AKI. Overall success
appears to be due to a combination approach of an e-alert and an AKI bundle, supported by overarching education and an AKI nurse to create a failsafe within the system.

- The e-alert must be timely and appropriately intrusive to trigger actions such as the completion of an AKI bundle.
- All healthcare workers, from healthcare assistants, nurses and doctors both undergraduate and postgraduate, should undergo AKI education with a focus on risk recognition, the unwell patient and task prioritisation.
- There must be a redundancy built into the system, be it AKI nurses or dedicated pharmacist review, to mitigate for human factors and ensure that alerts translate into action.”

Reducing acute kidney injury incidence and progression in a large teaching hospital (https://bmjopenquality.bmj.com/content/7/4/e000308)  Sykes L, Sinha S, Hegarty J, et al
Reducing acute kidney injury incidence and progression in a large teaching hospital BMJ Open Qual 2018;7:e000308. doi: 10.1136/bmjoq-2017-000308

“A number of acute hospitals have now demonstrated impactful successes in AKI reduction using traditional service improvement and QI methodologies. Almost all appear to have centred on a dedicated AKI nurse model plus e-alerting with supporting changes. This project adds value by highlighting another approach that does not require a new post with resultant rolling costs and risks. We believe that as our approach concentrated on embedding improved recognition and actions across the MDT, it has had the benefit of having increased our efficacy in acute care in our front-line teams.”

We have two further manuscripts currently under consideration of peer review which present difference aspects of AKI. The first looks at the impact of AKI in specific medical and surgical diagnoses, and the risks for critical care admission and mortality. The second looks at effect of AKI in patients with chronic kidney disease and the effect on mortality, renal replacement therapy and further episodes of AKI.

I would be grateful if you were able to consider the former and would also be very pleased to attend and discuss the work and its implications. I am currently working as a clinical research fellow in AKI and quality improvement, and as a general medical registrar part of my renal and general medical training. I have co-chaired sessions on AKI at the UK Kidney Week for the last 2 years and presented and co-chaired at the Royal Society of Medicine AKI Frontiers day last year.

Many thanks,
Lynne Sykes
Barbara Philips  (Brighton and Sussex Medical School, UK)

The scope of work is comprehensive and should lead to good recommendations. I have a comment for group 4. Could we consider the impact of AKI on drug dosing decisions particularly for drugs which are concentration dependent for effect? Initially dosing for such drugs may need to be the same or even increased from normal at the start of therapy to achieve sufficient concentration but then require modification according to renal function. This can be complex but we need to move away from the automatic reduction in drug dose often precipitated by the development of AKI. This is to take in to account changes in Vd, protein binding as well as factors such as renal replacement therapy and augmented renal clearance in early AKI recovery. It is unlikely we could deal with this subject comprehensively but I think the concepts and issues should be acknowledged.

Zhiyong Peng  (Zhongnan Hospital of Wuhan University, China)

1. Fluid management
What is the relationship between fluid overload and AKI? Is it association or causation? Patients with fluid overload are always complicated with shock or other critical illness, and AKI may be induced by shock or other critical illness. Fluid overload may be an associative phenomenon.

2. AKI diagnosis
The current criterion for AKI, serum creatinine, mainly reflects the GFR. However, the pathology of AKI occurs in tubules. The secretion of small molecules by the proximal tunnels represents a vital function for clearing endogenous solute from the circulation. Despite its central importance, this tubular secretory clearance is rarely measured. Can we consider it in our future AKI diagnosis?

Mauricio Berdugo  (bioMerieux)

We would like to thank the KDIGO committee for the opportunity to submit our comments for the scope of review for the upcoming KDIGO Guideline Controversies Conference. It is our hope that our comments will not only serve for review purposes, but will also serve as a reference for collaboration, with the shared goal of improving patient care. bioMerieux is committed to improving the health and care of patients around the world through research collaborations, educational initiatives and our portfolio of diagnostic tests and services in the fields of infectious disease, antimicrobial resistance, sepsis and acute kidney injury.
We found the scope of work and proposed questions to be relevant and comprehensive. We will therefore focus our comments on several areas of importance to bioMerieux’s mission to improve care and outcomes of patients at risk for AKI. Though our subsidiary Astute Medical, we have invested intense effort over the past decade working with our academic collaborators to discover, develop, and validate (including FDA clearance) novel AKI biomarkers, and importantly, to work with our clinical collaborators to develop and validate protocols for how clinicians can use these biomarkers in routine clinical practice to improve patient outcomes. The 2012 KDIGO AKI Guideline played a critical role in these efforts and we are delighted the Guideline will be reviewed for revision given the substantial progress that has been made since 2012 in managing patients at risk for AKI.

The role of biomarkers has been extensively studied and has advanced significantly since publication of the 2012 Guideline. The only biomarker test to date to have gained FDA clearance for routine clinical use in the United States ([TIMP-2]*[IGFBP7]) was published for the first time in 2013[1]. This unique biomarker test detects kidney stress that can lead to AKI has been approved for use in the United States and the European Union as an aid in the risk assessment for acute kidney injury. Since 2013, multiple publications have described performance and validation of the test in large multicenter studies of heterogeneous cohorts of critically ill patients as well as specific cohorts such as cardiac surgery[1-6] . Most importantly, randomized controlled trials [7-8] and quality initiatives for pragmatic routine use of the test [9] have published showing that use of the test in conjunction with protocols for patients at high risk of AKI can improve AKI outcomes.

Another important question to answer is whether there is sufficient evidence now available to warrant a change in the definitions/classification/staging system for AKI, related to the AKI/AKD/CKD continuum, early diagnosis of AKI remains a challenge for clinicians. Existing recommendations of acute kidney injury emphasize the importance of early intervention, risk assessment, and prevention. Guidelines recommend using a multi-parameter approach including clinical indicators of functional decline such as raised SCr levels, estimated glomerular filtration rate (eGFR), reduced urine output and other factors such as age, use of nephrotoxic drugs and comorbidities to identify at-risk patients. Increased SCr levels and reduced urine output are consequences of an earlier injury to the kidney and may not manifest for up to 48 hours after the injury has occurred; this can potentially cloud or delay the diagnosis of AKI and the kidney can rapidly progress to a more severe stage of AKI or even to CKD. Tissue Inhibitor of Metalloproteinase 2 and Insulin-like Growth Factor Binding Protein 7 ([TIMP-2]*[IGFBP-7]) levels rise rapidly early in the process of stress/injury to kidney cells, and thus in conjunction with the existing KDIGO diagnostic criteria, may help the clinician make a more timely and accurate assessment or diagnosis of the patient.
In one multicenter study of a large cohort of critically ill patients, AKI was clinically adjudicated by an expert panel of three critical care nephrologists who based their adjudication on KDIGO criteria, but considered numerous other patient clinical variables and could overrule the KDIGO criteria for any patient based on their expert judgement. In this analysis, [TIMP-2]*[IGFBP7] correlated to clinically adjudicated AKI better than to KDIGO criteria. Furthermore, in difficult cases where adjudicators overruled KDIGO criteria, the biomarker test discriminated well, providing evidence that [TIMP-2]*[IGFBP7] can add useful information to existing KDIGO criteria for assessing and diagnosing patients. In another study involving measurement of renal functional reserve prior to and 90 days after cardiac surgery [10], investigators found that patients who had a positive [TIMP-2][IGFBP7] test 4 hours after surgery but never developed AKI had significantly reduce renal functional reserve at 90 days. The results provide evidence that the test detects significant kidney stress/injury events that can lead to permanent kidney damage but that are not always manifest through the current KDIGO diagnostic criteria. The test therefore can be complimentary to the current diagnostic criteria that are based solely on SCr and urine output. Also peri-operative elevated values [[TIMP-2][IGFBP7] levels “may be superior to help identify patients at highest risk for subsequent decrease of RFR after cardiac surgery compared with postoperative time points [10].

In terms of the roles of biomarkers for risk-stratification and monitoring of patients for AKI, according to peer-reviewed literature, kidney stress can be monitored utilizing the combination urinary biomarker, [TIMP-2][IGFBP-7] . It is an in vitro diagnostic test used to measure tubular cell stress before acute kidney injury occurs in critically ill patients; this test identifies kidney stress much faster than the commonly used markers of serum creatinine and urine output. Based on most recent literature, TIMP-2/IGFBP-7 can be monitored pre-operatively, intraoperatively, or post-operatively. The main points from the evidence summarized in this briefing are from 3 validation and diagnostic accuracy studies (n=1,262) and 2 randomized controlled trials (n=397). The evidence shows that an increase in urinary TIMP2 and IGFBP7 in the critically ill a predictor of acute kidney injury.

Lastly, the role of biomarkers may also play a role in defining the criteria for classification of AKI caused by nephrotoxins. According to Griffin et al, the ability of [TIMP-2/IGFBP-7] to help the clinician identify early risk for AKI in critically ill patients may allow the clinician to identify kidney stress induced by nephrotoxins, therefore aiding the clinician in reducing the dose of the nephrotoxic drug, thus avoiding progression of kidney disease. [11]

References:

Dustin Dunham  (GE Healthcare - Life Sciences, Pharmaceutical Diagnostics)

Thank you for encouraging submission statements regarding scope of work for the 2019 KDIGO Controversies Conference on Acute Kidney Injury. We would like to submit the below topics and literature for consideration with special attention to Breakout Group 4: Nephrotoxins,
specifically regarding the prevention, management, and relative impact of contrast-associated AKI:

The exact pathophysiology of contrast-induced acute kidney injury (CI-AKI) is not well defined, however includes a complex cascade of events resulting in both ischemic and chemotoxic injury to the proximal renal tubules. Subclinical CI-AKI may occur in every patient exposed to iodinated contrast media (CM). Because there is a robust tubular repair capability, this process may not have any clinical consequences in healthy subjects. However, in patients with chronic kidney disease (CKD), especially those with underlying diabetes mellitus, who have a reduced number of functioning nephrons and an impaired ability to regenerate tubular epithelial cells, routine cardiac procedures using average doses of iodinated contrast can cause CI-AKI that is clinically important[1].

While several recent publications have questioned the true incidence of CI-AKI, particularly after intravenous administration of CM, the burden of acute renal events post-contrast enhanced procedures is categorical, particularly in higher-risk patients and complex procedures. There is strong correlation between the volume of contrast media administered and the incidence of AKI[2]. AKI occurring over course of percutaneous coronary intervention (PCI) has been associated with increased risk of bleeding, myocardial infarction, and death both in-hospital[3] and post-discharge[4]. Acute kidney injury in-turn perpetuates hospital readmission rates[5] and CI-AKI also leads to significant financial burden[6].

Susceptible patient populations such as oncology settings are further prone to poorer prognostic implications of AKI which is associated with prolonged hospital length of stay, increased hospitalization cost, and increased morbidity & mortality[7]. Recent retrospective review of 29 million inpatient visits suggests that acute renal events are more common in patients undergoing contrast enhanced computed tomography (CECT) versus those who do not, further that cancer patients are more prone to developing renal events versus non-cancer patients, and that adverse events parallel underlying degree of renal insufficiency and stages of CKD[8]. Serial insult in oncology patients due to CM-enhanced follow up examinations may further impact renal functional reserve (RFR), causing subclinical AKI to eventually develop into clinically relevant AKI[9].

Due to the frequency and poor prognostic implications posed by AKI, short-term adverse events, long-term adverse events, and potential financial burden, we recommend that comprehensive mitigation strategies be developed and employed. Further, AKI should be considered an important quality metric for healthcare systems as it is of strong clinical
relevance, measurable with persistent gap, actionable, and prevention of AKI results in improved downstream outcomes.

With regard to prevention strategies, the 2012 KDIGO Clinical Practice Guideline for the Evaluation and Management of CKD references avoidance of high osmolar agents, further, analysis of evidence indicates that wherever possible, isosmolar agents should be used in people with CKD at high risk for CI-AKI[10]. This recommendation is mirrored in a recent retrospective, propensity-score matched analysis where intravenous administration of isosmolar contrast media for CECT was not an independent risk factor for AKI, dialysis, or mortality among patients at the highest perceived risk of postcontrast AKI[11]. It also strongly parallels other key curricula noting the potential relative renal protective benefit of isosmolar contrast media evident within the American Society of Nephrology’s Onco-Nephrology Curriculum[12], Geriatric Nephrology Curriculum[13], and recently published consensus statement addressing CT related risk factors in oncology patients[14].

The above isosmolar recommendations may be further substantiated given recent contributions to the literature, including several meta-analyses[15,16,17] and systematic review[17] that were published after the 2012 KDIGO AKI Guideline, which reveal favorable risk reduction with isosmolar vs low-osmolar contrast, most notably within intra-arterial procedures versus intravenous administration. Procedural complexity and patient comorbidities are critical factors in the development of CI-AKI and efforts should be made to better explore and understand susceptible groups. A recent prospective, blinded, randomized control trial assessing cancer patients undergoing CECT suggested a more favorable safety profile with isosmolar contrast versus a low-osmolar comparator[18]. Robust real-world data has additionally rendered some potential external validation to findings from clinical trials for more complex procedures and at-risk patients such as those undergoing percutaneous cardiovascular intervention. McCullough et al data mined over 333,00 patient visits to better understand trends in contrast media utilization and prevalence of major adverse renal and cardiovascular events (MARCE). Results suggest that clinicians tend to utilize isosmolar contrast in older, sicker, and more comorbidity compromised patients and that after adjustment, isosmolar contrast was associated with 9.32% relative risk reduction in MARCE rate and 50% decrease in renal composite endpoint (events requiring dialysis) compared to low-osmolar contrast media[19].

Given the totality of data and recent supplementary evidence, we suggest that selection of isosmolar contrast media be considered as a recommendation for high-risk patients/procedures to complement a comprehensive multiprong mitigation strategy encompassing individual risk
assessment, peri-procedural hydration, judicious use of contrast in highest risk patients, withholding nephrotoxic medications when amenable, etc.

References:
2. Amin et al. JAMA Cardiol. 2017 Sep; 2(9): 1007–1012
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5815045/
3. Tsai et al. JACC Cardiovasc Intv. 2014;7;1–9
https://www.ncbi.nlm.nih.gov/pubmed/25446018
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6109283/
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6008879/
Thank you for your review and consideration.

Best regards,
Dustin M Dunham, DC, BCMAS Global Medical Leader - Cardiology Medical Affairs
Jeannette Rautenbach, MD Global Medical Leader - Radiology Medical Affairs

Tina Abdelnour  (Edwards Lifesciences)

All comments specific to Fluid Management Breakout (page 7):
Consider "Hemodynamic" Management, rather than just fluid, considering the large body of evidence that Intraoperative & Postoperative Hypotension are also strongly associated with postoperative AKI

Literature supporting Association of Hypotension with AKI:
2. Salmasi V, et al. 2016 Anesthesiology Relationship between Intraoperative Hypotension, Defined by Either Reduction from Baseline or Absolute Thresholds, and Acute Kidney & Myocardial Injury after Noncardiac Surgery: A Retrospective Cohort Analysis
4. Gu, et al. 2017 Intern J Cardiology Association between intraoperative hypotension and 30-day mortality, major adverse cardiac events, and acute kidney injury after non-cardiac surgery: A meta-analysis of cohort studies
Consider literature to support hemodynamic monitoring to implement Goal-Directed Fluid Therapy, as many of the 50+ RCTs demonstrated improvement in AKI rates with a goal-directed approach. The recent RELIEF trial also demonstrated that under-resuscitation in surgical patients worsens kidney outcomes

2. Calvo-Vecino BJA 2018 Effect of goal-directed haemodynamic therapy on postoperative complications in low-moderate risk surgical patients: a randomised controlled trial (FEDORA trial)
3. Myles NEJM 2018 Restrictive versus Liberal Fluid Therapy for Major Abdominal Surgery
4. Makaryus, Miller BJA 2018 Current concepts of fluid management in enhanced recovery pathways
5. Pinsky COCC 2016 Postoperative Hemodynamic Instability & Monitoring

Michael Joannidis  (Medical University Innsbruck, Austria)

Group 3: Topic 3: also would ask who should follow up patients after AKI

Group 5: Topic 1: Criteria for initiation of RRT should also include biomarkers as a subtopic
Effects of Intensive Blood Pressure Treatment on Acute Kidney Injury Events in the Systolic Blood Pressure Intervention Trial (SPRINT)


Background: Treating to a lower blood pressure (BP) may increase acute kidney injury (AKI) events.

Study Design: Data for AKI resulting in or during hospitalization or emergency department visits were collected as part of the serious adverse events reporting process of the Systolic Blood Pressure Intervention Trial (SPRINT).

Setting & Participants: 9,361 participants 50 years or older with 1 or more risk factors for cardiovascular disease.

Interventions: Participants were randomly assigned to a systolic BP target of <120 (intensive arm) or <140 mm Hg (standard arm).

Outcomes & Measurements: Primary outcome was the number of adjudicated AKI events. Secondary outcomes included severity of AKI and degree of recovery of kidney function after an AKI event. Baseline creatinine concentration was defined as the most recent SPRINT outpatient creatinine value before the date of the AKI event.

Results: There were 179 participants with AKI events in the intensive arm and 109 in the standard arm (3.8% vs 2.3%; HR, 1.64; 95% CI, 1.30-2.10; P < 0.001). Of 288 participants with an AKI event, 248 (86.1%) had a single AKI event during the trial. Based on modified KDIGO (Kidney Disease: Improving Global Outcomes) criteria for severity of AKI, the number of AKI events in the intensive versus standard arm by KDIGO stage was 128 (58.5%) versus 81 (62.8%) for AKI stage 1, 42 (19.2%) versus 18 (14.0%) for AKI stage 2, and 42 (19.2%) versus 25 (19.4%) for AKI stage 3 (P = 0.5). For participants with sufficient data, complete or partial resolution of AKI was seen for 169 (90.4%) and 94 (86.9%) of 187 AKI events in the intensive arm and 86 (86.9%) and 4 (4.0%) of 99 AKI events in the standard arm, respectively.

Limitations: Trial results are not generalizable to patients with diabetes mellitus or without risk factors for cardiovascular disease.

Conclusions: More intensive BP lowering resulted in more frequent episodes of AKI. Most cases were mild and most participants had complete recovery of kidney function.

Trial Registration: Registered at ClinicalTrials.gov with study number NCT01206062.

The Systolic Blood Pressure Intervention Trial (SPRINT), sponsored by the National Institutes of Health (NIH), was a study of blood pressure (BP) control in persons without diabetes mellitus at increased risk for developing cardiovascular disease (CVD). The relative hazard of the primary composite end point in SPRINT, which included myocardial infarction, acute coronary syndrome not resulting in myocardial infarction, stroke, acute decompensated heart failure, or death from cardiovascular causes, was significantly lower in the intensive arm (goal systolic BP [SBP] < 120 mm Hg) compared to the standard arm (goal SBP < 140 mm Hg). In addition, all-cause mortality was significantly lower in the intensive BP-lowering arm of the trial.

The frequency of serious adverse events (SAEs) in SPRINT was not significantly different between the 2 arms of the trial. SAEs that were anticipated to be higher in the intensive arm of the trial were a priori ascertained by the clinical sites and the SPRINT Safety Officer. Conditions of interest that were more frequent in the intensive arm included hypotension, syncope, electrolyte abnormalities, and acute kidney injury (AKI), typically noted in association with hospitalization. The goals of our detailed examination of AKI in SPRINT were to: (1) identify predictors of AKI resulting in either a hospitalization or emergency department (ED) visit, (2) adjudicate each of the reported AKI events, (3) determine the severity of and recovery from these events, and (4) explore effect modification of intensive versus standard BP lowering on AKI within each of the 6 predefined participant subgroups. Changes in kidney function that were noted based on SPRINT clinic laboratory results that did not result in a hospitalization or ED visit are described in 2 other publications.
been previously reported. The SPRINT cohort included calculations, and interim analysis and stopping rules have been previously reported. The SPRINT cohort included participants 50 years or older with SBPs ≥130 mm Hg, without a history of diabetes or stroke, and with increased risk for cardiovascular events, defined by 1 or more of the following: clinical or subclinical CVD other than stroke; chronic kidney disease (CKD), excluding polycystic kidney disease; 10-year risk for CVD ≥15% on the basis of the Framingham risk score; or age 75 years or older. Persons with diabetes mellitus, polycystic kidney disease, screening urine protein excretion >1 g/d or equivalent, symptomatic heart failure, ejection fraction <35%, or stroke were excluded from the trial. Participant enrollment into SPRINT occurred November 2010 to March 2013.

Methods

Study Population

SPRINT was a randomized controlled open-label trial sponsored by the National Heart, Lung, and Blood Institute (NHLBI), with cosponsorship by the National Institute of Diabetes and Digestive and Kidney Diseases, the National Institute of Neurological Diseases and Stroke, and the National Institute on Aging. The trial was approved by institutional review boards at participating study sites; all participants provided written informed consent. Participants from 102 clinical sites were randomly assigned to a target goal SBP of <120 mm Hg (intensive arm, n = 4,678) or <140 mm Hg (standard arm, n = 4,683). The design, eligibility, full trial protocol, sample size calculations, and interim analysis and stopping rules have been previously reported. The SPRINT cohort included participants 50 years or older with SBPs ≥130 mm Hg, without a history of diabetes or stroke, and with increased risk for cardiovascular events, defined by 1 or more of the following: clinical or subclinical CVD other than stroke; chronic kidney disease (CKD), excluding polycystic kidney disease; 10-year risk for CVD ≥15% on the basis of the Framingham risk score; or age 75 years or older. Persons with diabetes mellitus, polycystic kidney disease, screening urine protein excretion >1 g/d or equivalent, symptomatic heart failure, ejection fraction <35%, or stroke were excluded from the trial. Participant enrollment into SPRINT occurred November 2010 to March 2013.

Study Outcomes

Demographic data were collected at baseline, including self-reported race and ethnicity. Six prespecified subgroups of interest for all outcomes included the following: CVD at baseline (yes vs no), CKD at baseline (yes vs no), sex, race (black vs nonblack), age (<75 vs ≥75 years), and tertiles of baseline SBP (≤132, >132–<145, and ≥145 mm Hg). The presence of CKD at randomization was defined as estimated glomerular filtration rate of 20 to 59 mL/min/1.73 m² using the isotope-dilution mass spectrometry (IDMS)-traceable 4-variable MDRD (Modification of Diet in Renal Disease) Study equation; this definition defined the CKD cohort in SPRINT. Clinical and laboratory data were obtained at baseline and every 3 months thereafter. Serum creatinine was measured in a central laboratory by an enzymatic procedure using a Roche analyzer and was IDMS-traceable for calibration. Urine albumin was measured by an immunoturbidimetric method using a Roche analyzer. Urine albumin was quantified along with urine creatinine in random spot urine specimens, with urine albumin-creatinine ratio (in mg/g) used to account for urine concentration. AKI was defined using modified KDIGO (Kidney Disease: Improving Global Outcomes) criteria incorporating only serum creatinine concentration to assess for AKI stage (ignoring the component of urine output, which was not uniformly measured). These modified KDIGO criteria include the following AKI stages and serum creatinine definitions: stage 1, increase ≥0.3 mg/dL or increase of 1.5- to 2.0-fold from baseline; stage 2, increase greater than 2.0- to 3.0-fold from baseline; and stage 3, increase greater than 3.0-fold from baseline or ≥4.0 mg/dL with an acute increase of 0.5 mg/dL or need for renal replacement therapy.

At quarterly study visits, a structured interview was used to query participants about hospitalizations in the prior 3 months, as well as specific outcomes of interest, such as initiation of dialysis therapy. SAEs were also identified between visits if study staff were informed of them by participant report, electronic medical record notification, or other mechanism. SAEs were defined as events that were fatal or life-threatening, resulted in significant or persistent disability, or required or prolonged a hospitalization or medical events that the investigator judged to be a significant hazard or harm to the participant and required medical or surgical intervention to prevent hospitalization, death, or persistent disability. For selected SAEs, including AKI (as either the primary reason for hospitalization or a part of the hospitalization), clinic staff were required to obtain medical records of the event for review by the medical safety officer, including ED notes for ED visits and the admission history and physical and discharge summary for hospitalizations. The medical safety team at the Coordinating Center reviewed the medical records from hospitalizations and ED visits and from SAE reports, and the team recorded AKI if it was noted on admission or occurred during a hospitalization or ED visit and was reported in the hospital discharge summary as a primary or main secondary diagnosis. If the discharge summary did not list AKI as a primary or secondary diagnosis, the record was not reviewed to determine whether an AKI event may have occurred but was not listed explicitly. In some cases, these records included all laboratory creatinine values obtained during the admission, whereas in other cases, only creatinine values recorded in the discharge summary and/or the admission note and/or progress notes were used to ascertain the occurrence and severity of AKI. The Medical Dictionary for Regulatory Activities (MedDRA) was used to classify safety events. Coding was performed at the Coordinating Center, and up to 3 codes were assigned to each safety event.

All SAEs and ED visits classified as involving an AKI event by the safety team were reviewed in a blinded fashion by 2 nephrologists or physician experts in outcomes adjudication to determine baseline and peak creatinine values, modified KDIGO stage of AKI, the underlying primary cause of the AKI, and whether it was thought that SPRINT participation caused or contributed to the event. Baseline creatinine concentration was defined as the most recent SPRINT outpatient creatinine value before the date of the AKI event. Disagreements regarding baseline and peak creatinine values, AKI stage, or whether SPRINT participation caused or contributed to the event were resolved by a single third adjudicator (M.V.R.). After
blinded adjudication, 54 of 402 events were not thought to represent AKI by modified KDIGO criteria. Therefore, the rest of this study reports on the 348 events adjudicated as AKI.

Recovery of kidney function was determined by comparing the peak recorded serum creatinine value with the lowest outpatient SPRINT creatinine value obtained in the subsequent 365 days. Recovery was classified as complete (recovery to within 20% of pre-AKI serum creatinine concentration), partial (recovery to within 30% of pre-AKI serum creatinine value), or nonrecovery (no decline in serum creatinine or a decline not reaching the "within 30% of baseline value" threshold).

**Statistical Analyses**

Statistical analyses were conducted at the Coordinating Center using SAS software, version 9.4 (SAS Institute Inc). Baseline characteristics were compared among participants who did and did not have AKI during the trial with use of t test or Wilcoxon rank sum test for continuous variables and χ² test for discrete or categorical variables. Continuous variables are presented as either mean ± standard deviation if normally distributed or median with 25th to 75th percentile if not normally distributed.

Time until first occurrence of AKI was compared between the 2 study arms with the use of the intention-to-treat approach for all randomly assigned participants. We used Cox proportional hazards regression, with 2-sided tests at the 5% level of significance, with stratification by clinical site.

An assessment for nonproportionality of hazards was made with the addition of the interaction between log (time) and the intervention. Follow-up time was censored at the time of the final event ascertainment. Interactions between treatment effect and prespecified subgroups were assessed using a likelihood ratio test for interaction. Baseline variables thought to be related to time to the development of AKI were assessed first in univariate models and then added as a group to the primary analysis model.

In exploratory analyses, participants with multiple AKI events were analyzed according to data obtained at the first occurrence of AKI to determine whether these variables were predictive of recurrence. These exploratory analyses used time from the first episode of AKI to first recurrence, with censoring time set at the participant’s last visit. The association of AKI events with primary and secondary end points was evaluated using the Cox proportional hazards model, with a time-varying covariate for the first AKI episode.

**Results**

**Overview**

The SPRINT cohort consists of 9,361 participants who were followed up for a mean of 3.26 years before the BP intervention was stopped early on August 20, 2015,

![Figure 1. CONSORT (Consolidated Standards of Reporting Trials) diagram. Abbreviation: BP, blood pressure.](image-url)
after the NIH accepted the recommendation of the Data and Safety Monitoring Board due to benefit in the intensive arm on the primary outcome (Fig 1). This study reports on AKI events occurring through August 20, 2015.

### Incidence and Correlates of Adjudicated AKI Events

There were 348 AKI events in 288 (3.0%) participants. Baseline characteristics of study participants, stratified by the presence or absence of at least one AKI event, are shown in Table 1. Baseline characteristics associated with the presence or absence of at least one AKI event, are values for categorical variables are given as count (percentage); for continuous variables, as mean ± standard deviation. Conversion factors for units: creatinine in mg/dL to μmol/L, ×88.4; glucose in mg/dL to mmol/L, ×0.0555.

Abbreviations: ACR, albumin-creatinine ratio; AKI, acute kidney injury; BMI, body mass index; CKD, chronic kidney disease; CVD, cardiovascular disease; DBP, diastolic blood pressure; ECG, echocardiogram; eGFR, estimated glomerular filtration rate; SBP, systolic blood pressure.

Subclinical CVD includes ≥50% stenosis of a coronary, carotid, or lower-extremity artery; abdominal aortic aneurysm ≥5 cm with or without repair; coronary artery calcium score ≥400 Agatston units; low ankle-brachial index (≤0.90); left ventricular hypertrophy by computer ECG reading, ECG report, or other cardiac imaging procedure.

Clinical CVD includes myocardial infarction; acute coronary syndrome with or without ECG changes at rest, ECG changes on graded exercise test, or positive cardiac imaging study; coronary revascularization; carotid endarterectomy or carotid stenting; and peripheral arterial disease with revascularization.

#### Table 1. Baseline Clinical Characteristics by Occurrence of AKI

<table>
<thead>
<tr>
<th>Baseline Characteristics</th>
<th>Intensive Treatment</th>
<th>Standard Treatment</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>No AKI (n = 4,499)</td>
<td>AKI (n = 179)</td>
<td></td>
</tr>
<tr>
<td>Age ≥ 75 y</td>
<td>1,250 (27.8%)</td>
<td>67 (37.4%)</td>
<td>0.005</td>
</tr>
<tr>
<td>Age, y</td>
<td>67.8 ± 9.3</td>
<td>70.7 ± 10.0</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Female sex</td>
<td>1,635 (36.3%)</td>
<td>49 (27.4%)</td>
<td>0.01</td>
</tr>
<tr>
<td>Race or ethnic group</td>
<td></td>
<td></td>
<td>0.002</td>
</tr>
<tr>
<td>African American</td>
<td>1,307 (29.1%)</td>
<td>72 (40.2%)</td>
<td></td>
</tr>
<tr>
<td>Hispanic</td>
<td>493 (11.0%)</td>
<td>10 (5.6%)</td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td>97 (2.2%)</td>
<td>1 (0.6%)</td>
<td></td>
</tr>
<tr>
<td>White</td>
<td>2,602 (57.8%)</td>
<td>96 (53.6%)</td>
<td></td>
</tr>
<tr>
<td>CKD</td>
<td>1,233 (27.5%)</td>
<td>97 (54.5%)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Serum creatinine, mg/dL</td>
<td>1.1 ± 0.3</td>
<td>1.4 ± 0.5</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>eGFR, mL/min/1.73 m²</td>
<td>72.2 ± 20.4</td>
<td>59.8 ± 24.4</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Urinary ACR, mg/g</td>
<td>40.3 ± 161.8</td>
<td>139.1 ± 407</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>CVD</td>
<td>889 (19.8%)</td>
<td>51 (28.5%)</td>
<td>0.004</td>
</tr>
<tr>
<td>Subclinical</td>
<td>155 (3.4%)</td>
<td>6 (3.4%)</td>
<td>0.9</td>
</tr>
<tr>
<td>Clinical</td>
<td>734 (16.3%)</td>
<td>45 (25.1%)</td>
<td>0.002</td>
</tr>
<tr>
<td>Smoking status</td>
<td>0.07</td>
<td></td>
<td>0.002</td>
</tr>
<tr>
<td>Never</td>
<td>1,986 (44.3%)</td>
<td>64 (35.8%)</td>
<td></td>
</tr>
<tr>
<td>Former</td>
<td>1,892 (42.2%)</td>
<td>85 (47.5%)</td>
<td></td>
</tr>
<tr>
<td>Current</td>
<td>609 (13.6%)</td>
<td>30 (16.8%)</td>
<td></td>
</tr>
<tr>
<td>BMI, kg/m²</td>
<td>29.9 ± 5.8</td>
<td>30.0 ± 5.8</td>
<td>0.9</td>
</tr>
<tr>
<td>SBP, mm Hg</td>
<td>139.6 ± 15.7</td>
<td>142.1 ± 17.1</td>
<td>0.03</td>
</tr>
<tr>
<td>DBP, mm Hg</td>
<td>78.3 ± 11.8</td>
<td>77.1 ± 13.5</td>
<td>0.2</td>
</tr>
<tr>
<td>SBP tertile</td>
<td></td>
<td>0.2</td>
<td></td>
</tr>
<tr>
<td>≤132 mm Hg</td>
<td>1,534 (34.1%)</td>
<td>49 (27.4%)</td>
<td></td>
</tr>
<tr>
<td>&gt;132-&lt;145 mm Hg</td>
<td>1,429 (31.8%)</td>
<td>60 (33.5%)</td>
<td></td>
</tr>
<tr>
<td>≥145 mm Hg</td>
<td>1,536 (34.1%)</td>
<td>70 (39.1%)</td>
<td></td>
</tr>
<tr>
<td>Fasting glucose, mg/dL</td>
<td>98.8 ± 13.6</td>
<td>100.3 ± 16.5</td>
<td>0.2</td>
</tr>
<tr>
<td>Statin use</td>
<td>1,896 (42.5%)</td>
<td>82 (45.8%)</td>
<td>0.4</td>
</tr>
</tbody>
</table>

Note: Values for categorical variables are given as count (percentage); for continuous variables, as mean ± standard deviation. Conversion factors for units: creatinine in mg/dL to μmol/L, ×88.4; glucose in mg/dL to mmol/L, ×0.0555.

Statin use: information not provided.
intravascular volume depletion, followed by hypotension (Table 3). In both the CKD and non-CKD cohorts, 10.0% of cases of AKI in the intensive arm and 2.3% of cases in the standard arm were thought to be secondary to the intervention. By multivariable analysis, risk factors for time to development of an AKI event included older age, nonwhite race, lower baseline estimated glomerular filtration rate, and presence of CVD at baseline (Table 4).

**Effects of Intensive BP Lowering on AKI by Prespecified Subgroups**

There were 179 participants with AKI events in the intensive arm and 109 in the standard arm (3.8% vs 2.3%). The hazard ratio (HR) for AKI in the intensive versus standard arms was 1.64 (95% confidence interval [CI], 1.30–2.10; Fig 2). The effects of the intervention on AKI rate were consistent across the prespecified subgroups (baseline CVD, baseline CKD, sex, race, age, and baseline SBP; Fig 3). There were no significant interactions between treatment and subgroup (P value range, 0.06–0.9).

**Post-AKI Events**

Among participants with sufficient data to determine recovery, complete or partial resolution of AKI was seen for 169 (90.4%) and 9 (4.8%) of the 187 AKI events in the intensive arm and 86 (86.9%) and 4 (4.0%) of the 99 AKI events in the standard arm, respectively. Only 14 (5.6%) events required dialysis for the treatment of AKI and 50% of these participants subsequently became dialysis independent.

Exploratory analyses were conducted to examine the risk for events following AKI. When including first AKI event as a time-varying covariate in a Cox model accounting for randomized group, AKI events were found to be associated with higher risks for both the primary SPRINT outcome (501 events in the no-AKI group [5.5%] vs 61 events in the AKI group [21.2%]; HR, 2.0 [95% CI, 1.2–3.1]; P = 0.004) and death from any cause (320 events in the no-AKI group [3.5%] vs 45 events in the AKI group [15.6%]; HR, 5.6 [95% CI, 4.0–7.8]; P < 0.001). Causes of death by randomly assigned arm are shown in Table 5.

**Discussion**

In SPRINT, participants randomly assigned to the intensive BP-lowering arm had significantly lower rates of the trial’s primary composite end point, as well as lower rates of death and no difference in the total number of SAEs compared with participants randomly assigned to the standard arm. These benefits were offset by a subset of SAEs that were more common in participants in the intensive treatment arm, including AKI. Of participants who developed AKI in either arm of the trial, AKI stage, as assessed by modified KDIGO criteria, was in the lowest stage of severity for >50% of AKI events. AKI events were mainly attributed to volume depletion and in ~90% of persons in either study arm resulted in complete or partial recovery of kidney function. The need for dialytic therapy for the treatment of AKI was exceedingly rare (0.15%). Moreover, the rate of development of AKI in SPRINT was steady throughout the trial; specifically, AKI was not more common during the initial year, when participants generally experienced the most active titration of antihypertensive medications (Fig 2). We hypothesize that the increased frequency of AKI events in the intensive arm may have been due to the lower baseline SBP that resulted in increased risk for BP falling below the autoregulatory threshold for kidney perfusion when a volume-depleting illness and/or hypotension occurred.

Episodes of AKI, including those not severe enough to require dialysis, have consistently been shown to associate...
with increased risk for in-hospital mortality. In this trial, we found that AKI was associated with increased risk for the primary SPRINT outcome and for death from any cause. Moreover, AKI has the potential to cause significant morbidity because AKI can contribute to progressive CKD and, in some instances, end-stage kidney disease. Risk factors for AKI include the presence of CKD and older age, although participants in the intensive arm had increased risk for AKI events in SPRINT that resulted in longer-term deterioration of kidney function allays this latter concern. In addition, participants in the intensive arm still had reduced risk for the primary SPRINT outcome and all-cause mortality compared with those in the standard arm.

These findings help in interpreting the risk-benefit ratio of the SPRINT results and are important to consider when developing clinical guidelines for the management of hypertension.

Comparison of the SPRINT AKI results with other hypertension trials is difficult for several reasons. First, a minority of hypertension trials provide information on the incidence of AKI. Second, persons with CKD, a major risk factor for AKI, have often been excluded from hypertension trials. Furthermore, there is no consensus regarding how to define recovery of kidney function after AKI; a recent meta-analysis demonstrated that there was a broad range of definitions, including variability in the timing of post-AKI creatinine measurements and in the thresholds used for recovery based on serum creatinine concentrations. We chose to report recovery of kidney function using 2 different definitions. UK guidelines adopted a return of serum filtration rate that had been seen in previous hypertension trials could adversely affect kidney function in SPRINT participants, both on a long-term basis and by increasing the risk for AKI events. The paucity of AKI events in SPRINT that resulted in longer-term deterioration of kidney function allays this latter concern. In addition, although participants in the intensive arm had increased risk for AKI events, participants in the intensive arm still had reduced risk for the primary SPRINT outcome and all-cause mortality compared with those in the standard arm. These findings help in interpreting the risk-benefit ratio of the SPRINT results and are important to consider when developing clinical guidelines for the management of hypertension.
creatinine concentration to within 20% of baseline as a
definition of recovery; the Program to Improve Care in
Acute Renal Disease (PICA RD) used the same defini-
tion.7,8 Other investigators proposed a threshold of re-
covery to within 30% of the baseline serum creatinine
concentration and cite increased risk for CKD if recovery
does not occur.9

There are several strengths of these analyses,
including the large sample size; inclusion of participants
with risk factors for AKI, including CKD at baseline and
older age; wide separation between achieved BP s in the
trial arms; and capture of major diagnoses from virtually
all hospitalizations. There are also important limi-
tations to these analyses. First, serum creatinine
data—in the hospital and thereafter—were relatively
sparse and collected based on the trial protocol
(monthly for 3 months, then biannually), rather than
based on clinical indications. In other words, post-
discharge serum creatinine determinations were not
uniformly obtained. Second, site staff were unblinded
and could have looked more carefully for AKI events in
records of participants randomly assigned to the arm
with intensive BP lowering. Third, although adjudica-
tors were blinded to treatment assignment, in some
cases, they may have been able to infer the treatment
assigned to individual participants. Fourth, AKI events
that were managed in the outpatient setting were not
captured in this analysis; however, it is likely that these
events were not severe enough to warrant either a
hospital admission or evaluation in an ED. Note that
data for changes in kidney function based on SPRINT
laboratory data only will be the subject of 2 additional
studies. Thus, the AKI prevalence reported here is
likely an underestimation of the true AKI incidence in
the trial, but captures all AKI events of sufficient severity
to be associated with a hospitalization. Finally, these
results are generalizable to only the study population
and thus should be extrapolated cautiously to other
patient populations, including those with diabetes
mellitus or polycystic kidney disease, persons at low
risk for cardiovascular events, and institutionalized
patients.

In sum, more intensive BP lowering in persons with
hypertension at high risk for CVD resulted in an increase
in risk for AKI, although episodes of AKI were generally
mild and largely reversible. Patients and physicians who
undertake more intensive BP-lowering strategies should
be alert for the risk for AKI, particularly among older

---

**Figure 2.** Cumulative hazard plot for acute kidney injury. Abbreviation: CI, confidence interval.
patients and patients with CKD. However, for patients thought to benefit in terms of CVD prevention, fear of AKI should not preclude an intensive BP-lowering strategy.

Table 5. Causes of Death for 45 Participants With Any AKI Event Who Died

<table>
<thead>
<tr>
<th>Cause of Death</th>
<th>Intensive Arm</th>
<th>Standard Arm</th>
</tr>
</thead>
<tbody>
<tr>
<td>CHF</td>
<td>3</td>
<td>2</td>
</tr>
<tr>
<td>Cancer</td>
<td>10</td>
<td>3</td>
</tr>
<tr>
<td>MI/coronary heart disease</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>Other noncardiac/nonstroke death</td>
<td>7</td>
<td>8</td>
</tr>
<tr>
<td>Stroke</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Sudden cardiac death</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>Unclassifiable</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>Still under adjudication</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Accident/injury/suicide/homicide</td>
<td>2</td>
<td>0</td>
</tr>
<tr>
<td>Total</td>
<td>26</td>
<td>19</td>
</tr>
</tbody>
</table>

Note: Values are given as number of participants. Abbreviations: AKI, acute kidney injury; CHF, congestive heart failure; MI, myocardial infarction.

Figure 3. Forest plot of acute kidney injury. The dashed vertical line represents the hazard ratio for the overall study population. Box sizes are proportional to the precision of the estimates (with larger boxes indicating a greater degree of precision). The subgroup of no previous chronic kidney disease (CKD) includes some participants with unknown CKD status at baseline. Black race includes Hispanic black and black as part of a multiracial identification. Abbreviations: BP, blood pressure; CI, confidence interval; CVD, cardiovascular disease.
Geriatric Medicine (KMS), and Division of Public Health Sciences, Department of Biostatistical Sciences (LCL, DMR), Wake Forest School of Medicine, Wake Forest University, Winston-Salem, NC; Section of Nephrology, Department of Medicine, Zablocki VA Medical Center (DFW); Division of Nephrology, Department of Medicine, Medical College of Wisconsin (DFW), Milwaukee, WI; Department of Clinical Research, Veterans Affairs Hospital, Kansas City, MO (TBW); University of Tennessee Health Science Center (BMW); Department of Veterans Affairs Medical Center, Memphis, TN (BMW); Division of Nephrology and Hypertension, Henry Ford Hospital, Detroit, MI (KU); Renal Division, Department of Medicine, Emory University School of Medicine, Atlanta, GA (FR-O); Section of Nephrology, Department of Medicine, University of Illinois at Chicago, Chicago, IL (ACP, JPL); Division of Nephrology, Department of Medicine, Medical University of South Carolina, Charleston, SC (RP, RCC); Division of Preventive Medicine, University of Alabama at Birmingham, Birmingham, AL (CEL); Division of Nephrology/Hypertension, Vanderbilt University Medical Center, Nashville, TN (UBL, JPD); VA New York Harbor Healthcare System and New York University School of Medicine, New York, NY (LAK); Division of Nephrology and Hypertension, Mayo Clinic, Jacksonville, FL (WEH); Division of Renal Diseases & Hypertension, University of Minnesota, Minneapolis, MN (PED); Division of Nephrology and Hypertension, Department of Medicine, University Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, OH (MD); Division of Nephrology & Hypertension, University of Utah (AKC, SB); Medical Service, Department of Veterans Affairs, Salt Lake City Healthcare System, Salt Lake City, UT (AKC, SB); Division of Nephrology, The Ohio State University Wexner Medical Center, Columbus, OH (UB); Division of Kidney Urologic and Hematologic Diseases, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD (PLK); and Division of Nephrology, Department of Medicine, Stanford University School of Medicine, Palo Alto, CA (GMC).

Address for Correspondence: Michael V. Rocco, MD, MSCE, Internal Medicine/Nephrology, Wake Forest School of Medicine, Medical Center Blvd, Winston-Salem, NC 27157-1053. E-mail: mrocco@wakehealth.edu

Authors’ Contributions: Research idea and study design: MVR, KMS, GMC, DMR; data acquisition: all authors except DMR and LCL; as these authors were involved with adjudication of AKI events, plus analysis/interpretation: MVR, KMS, GMC, LCL; statistical analysis: LCL; supervision or mentorship: MVR, KMS, GMC. Each author contributed important intellectual content during manuscript drafting or revision and accepts accountability for the overall work by ensuring that questions pertaining to the accuracy or integrity of any portion of the work are appropriately investigated and resolved.

Support: Supported by contracts (HHSN268200900040C, HHSN268200900046C, HHSN268200900047C, HHSN268200900048C, and HHSN268200900049C) and an interagency agreement (A-HL-13-002-001) from the NIH, including the NHLBI, the National Institute of Diabetes and Digestive and Kidney Diseases, the National Institute on Aging, and the National Institute of Neurological Disorders and Stroke. Several study sites were supported by Clinical and Translational Science Awards funded by the National Center for Advancing Translational Sciences of the NIH (Case Western Reserve University: UL1TR000439; Ohio State University: UL1TR0025755; University of Pennsylvania: UL1TR0024134 and UL1TR000003; Boston University: UL1TR0025771; Stanford University: UL1TR000083; Tufts University: UL1TR0025752, UL1TR000073, and UL1TR001064; University of Illinois: UL1TR000080; University of Pittsburgh: UL1TR000005; University of Texas Southwestern: 9U5TR00017-06; University of Utah: UL1TR000105-05; Vanderbilt University: UL1TR000445; George Washington University; UL1TR000075; University of California, Davis: UL1TR000002; University of Florida: UL1TR000064; University of Michigan: UL1TR000443; and Tulane University: P30GM103337 Centers of Biomedical Research Excellence Award National Institute of General Medical Sciences). The trial was also supported in part with respect to resources and the use of facilities by the Department of Veterans Affairs. Azilsartan and chlorthalidone (combined with azilsartan) were provided by Takeda Pharmaceuticals International Inc. The SPRINT Steering Committee was responsible for the design and conduct of the study, including the collection and management of the data. Scientists at the NIH as a group and the principal investigator of the Veterans Affairs clinical network had 1 vote on the Steering Committee of the trial. There were 7 voting members of the Steering Committee. The NIH, the US Department of Veterans Affairs, and the US government had no role in analysis and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Financial Disclosure: Dr Freedman reports research support from Novartis Pharmaceuticals and serving as a consultant for Ionis Pharmaceuticals. Dr Lewis reports serving as a consultant for Sanofi and Acaeeogen. The other authors declare that they have no other relevant financial interests.

Acknowledgements: We thank the study participants, without whom this trial would not have been possible.

Disclaimer: The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH, the US Department of Veterans Affairs, or the US government.

Peer Review: Received April 7, 2017. Evaluated by 3 external peer reviewers, with editorial input from a Statistics/Methods Editor and an Acting Editor-in-Chief (Associate Editor James S. Kaufman, MD). Accepted in revised form August 25, 2017. The involvement of an Acting Editor-in-Chief to handle the peer-review and decision-making processes was to comply with AJKD’s procedures for potential conflicts of interest for editors, described in the Information for Authors & Journal Policies.

References


Kidney Damage Biomarkers and Incident Chronic Kidney Disease During Blood Pressure Reduction

A Case–Control Study

William R. Zhang, BS; Timothy E. Craven, MSPH; Rakesh Malhotra, MD; Alfred K. Cheung, MD; Michel Chonchol, MD; Paul Drawz, MD; Mark J. Sarnak, MD, MS; Chirag R. Parikh, MD, PhD; Michael G. Shlipak, MD, MPH*; and Joachim H. Ix, MD, MAS*; for the SPRINT Research Group†

Background: Whether the increased incidence of chronic kidney disease (CKD) during intensive systolic blood pressure (SBP) lowering is accompanied by intrinsic kidney injury is unknown.

Objective: To compare changes in kidney damage biomarkers between incident CKD case participants and matched control participants as well as between case participants in the intensive (<120 mm Hg) versus the standard (<140 mm Hg) SBP management groups of SPRINT (Systolic Blood Pressure Intervention Trial).

Design: Nested case–control study within SPRINT.

Setting: Adults with hypertension without baseline kidney disease.

Participants: Case participants (n = 162), who developed incident CKD during trial follow-up (128 in the intensive and 34 in the standard group), and control participants (n = 162) without incident CKD, who were matched on age, sex, race, baseline estimated glomerular filtration rate, and randomization group.

Measurements: 9 urinary biomarkers of kidney damage were measured at baseline and at 1 year. Linear mixed-effects models were used to estimate 1-year biomarker changes.

Results: Higher concentrations of urinary albumin, kidney injury molecule-1, and monocyte chemoattractant protein-1 at baseline were significantly associated with greater odds of incident CKD (adjusted odds ratio per doubling: 1.50 [95% CI, 1.14 to 1.98], 1.51 [CI, 1.05 to 2.17], and 1.70 [CI, 1.13 to 2.56], respectively). After 1 year of blood pressure intervention, incident CKD case participants in the intensive group had significantly greater decreases in albumin-creatinine ratio (ACR), interleukin-18, anti–chitinase-3-like protein 1 (YKL-40), and uromodulin than the matched control participants. Compared with case participants in the standard group, those in the intensive group had significantly greater decreases in ACR, β2-microglobulin, α1-microglobulin, YKL-40, and uromodulin.

Limitation: Biomarker measurements were available only at baseline and 1 year.

Conclusion: Incident CKD in the setting of intensive SBP lowering was accompanied by decreases, rather than elevations, in levels of kidney damage biomarkers and thus may reflect benign changes in renal blood flow rather than intrinsic injury.

Primary Funding Source: National Institute for Diabetes and Digestive and Kidney Diseases.

See also: Web-Only Supplement

Annals.org doi:10.7326/M18-1037

This article was published at Annals.org on 23 October 2018.

* Drs. Shlipak and Ix are senior authors who contributed equally to this work.
† For members of the SPRINT Research Group, see the Appendix (available at Annals.org).

The association of lower blood pressures with substantial cardiovascular and mortality benefit is well established (1-3). SPRINT (Systolic Blood Pressure Intervention Trial) was a pivotal randomized controlled trial demonstrating that intensive systolic blood pressure (SBP) reduction to less than 120 mm Hg decreased rates of major cardiovascular events and all-cause mortality compared with standard management to less than 140 mm Hg (4). Despite these benefits, a notable harm was a more than 3-fold incidence of chronic kidney disease (CKD) in the intensive versus the standard group. Nonetheless, recent guidelines by the American College of Cardiology and American Heart Association lowered blood pressure targets for hypertension diagnosis and management (5). These policy changes may dramatically increase the incidence of CKD at the population level and pose an important public health concern. However, in the setting of intensive blood pressure lowering, kidney function decline measured by creatinine levels may be a benign manifestation of reduced renal blood flow. Thus, uncertainty remains regarding whether incident CKD that develops during intensive blood pressure lowering is accompanied by intrinsic kidney injury or instead reflects hemodynamic changes.

To address this question, we designed a nested case–control study of incident CKD case participants and matched control participants within SPRINT. We used a panel of urinary biomarkers of kidney damage measured at baseline and at 1 year of follow-up. Our aims were to determine whether baseline biomarker concentrations were associated with incident CKD, whether changes in urinary biomarkers were associated with risk for incident CKD, and whether the extent of biomarker changes differed between participants with CKD that developed during intensive versus standard SBP management. We hypothesized that biomarker changes among CKD case participants in the intensive...
group would represent benign changes in renal blood flow rather than intrinsic tissue injury.

Methods

Study Design and Population

SPRINT was a randomized, controlled, open-label study of intensive (targeting <120 mm Hg) versus standard (targeting <140 mm Hg) SBP therapy in persons at high cardiovascular risk and without diabetes (4). A total of 9361 participants were enrolled between November 2010 and March 2013 at 102 sites in the United States and Puerto Rico. Among these participants, 2646 (28%) had baseline CKD, defined as an estimated glomerular filtration rate (eGFR) less than 60 ml/min/1.73 m² by the Modification of Diet in Renal Disease (MDRD) equation. Full details of the study protocols are published elsewhere (6).

Among participants without CKD at baseline, the SPRINT protocol defined incident CKD as a reduction in eGFR of 30% or more from baseline, on the basis of the MDRD equation, and an eGFR less than 60 ml/min/1.73 m² confirmed on 2 serial measurements at least 3 months apart. During a mean SPRINT follow-up of 3.26 years, incident CKD developed in 162 participants, 128 in the intensive and 34 in the standard group. Of the 162 incident CKD cases, 26.5% (n = 43) were diagnosed by the 1-year follow-up visit, whereas the remaining cases were diagnosed afterward. In the SPRINT Kidney Tubule Health ancillary project, we defined baseline CKD by using the CKD Epidemiology Collaboration equation with both cystatin C and creatinine (resulting in 2503 cases of baseline CKD), which accounts for the modest difference in the number of incident CKD cases in our study (n = 162) relative to the original publication (n = 154). For each incident CKD case participant, we used prevalent control sampling to select 1 matched control participant in whom CKD had not developed by the end of follow-up. We used a hierarchical matching scheme prioritizing the following factors, in order—randomization group, age (within 5 years), sex, race, and baseline eGFR (within 5 ml/min/1.73 m²)—to account for these potential confounders. One control participant could not be matched on race after being matched on randomization group, eGFR, and age. The SPRINT Research Group approved the study protocol, which complies with the Declaration of Helsinki.

Measurement of Urinary Biomarkers of Kidney Damage

Our panel included the following 9 urinary biomarkers: albumin–creatinine ratio (ACR), interleukin-18 (IL-18), kidney injury molecule-1 (KIM-1), neutrophil gelatinase-associated lipocalin (NGAL), monocyte chemoattractant protein-1 (MCP-1), anti–chitinase-3-like protein 1 (YKL-40), β2-microglobulin (β₂M), α₁-microglobulin (α₁M), and uromodulin. These proteins have been well studied in kidney disease as direct markers of kidney damage, particularly in the settings of drug nephrotoxicity (7, 8) and acute kidney injury (9–11). In general, the biomarkers reflect glomerular injury (ACR), tubular injury and fibrosis (IL-18, KIM-1, NGAL, and MCP-1), tubular injury repair (YKL-40), proximal tubular dysfunction (β₂M and α₁M), and loop of Henle protein production (uromodulin).

We used urine specimens collected from CKD case and control participants at randomization (baseline) and at the 1-year follow-up visit. All specimens were stored continuously at −80 °C, without previous freeze–thaw, until measurement. Biomarkers were measured at the University of Vermont Laboratory for Clinical Biochemistry Research. Urinary biomarkers from both baseline and 1 year were measured contemporaneously to minimize the influence of laboratory drift. Biomarkers were measured simultaneously by using multiplex immunoassays from Meso Scale Discovery—except for α₁M, which was measured by using the BN II nephelometer assay (Siemens). Urinary creatinine was measured by using a Cobas c 311 clinical analyzer (Roche Diagnostics). Details regarding assay methods are shown in Appendix Tables 1 and 2 (available at Annals.org). Biomarker concentrations below the lower limit of detection were imputed with a value calculated by subtracting a small number from the limit of detection. Laboratory personnel were blinded to clinical information about the participants, and specimens were evaluated in random order. Except for urinary ACR and α₁M, all biomarkers were measured in duplicate, and results were averaged to improve precision.

Covariates

In addition to matching factors, covariates examined included baseline and 1-year SBP and diastolic blood pressure; number of antihypertensive medications used; angiotensin-converting enzyme inhibitor or angiotensin-receptor blocker use; and baseline total and high-density lipoprotein cholesterol concentrations, body mass index, history of clinical cardiovascular disease, history of chronic heart failure, and smoking status. Covariates were selected on the basis of evidence from previous studies (12) and were collected as part of the parent trial. Our prespecified analytic plan included statistical adjustments for baseline covariates that differed between case and control participants within each intervention group.

Statistical Analysis

First, we summarized baseline characteristics in CKD case and matched control participants, stratified by intervention group, and tested for differences by using univariate conditional logistic regression models. Next, we compared baseline biomarker concentrations between case and matched control participants in our overall study sample, as well as stratified by intervention group, by fitting separate conditional logistic regression models for each biomarker, adjusting for baseline SBP and urinary creatinine levels. Because of their skewed distributions, biomarker concentrations were summarized by using geometric means and SEs. All models, except those for ACR, were adjusted for log₂-transformed urinary creatinine concentrations to account for urine tonicity.
We assessed the potential for bias due to the choice of prevalent control sampling at the end of follow-up rather than incidence density sampling. To account for these potential control selection biases, we used the semiparametric weighted estimator proposed by Landsman and Graubard (13). We then recalculated the associations between biomarkers at baseline and case–control status by using sample weights. Case participants were assigned a weight of 1, because all participants with incident CKD were included in the sample. Initial weights for control participants were calculated at each distinct CKD onset time as the inverse probability of selection after inclusion of subsequent case participants as potential control participants to simulate incidence density sampling. After rescaling these weights by dividing them by their mean value, we calibrated them to the predicted weights by using the matching factors. This process resulted in the model-adjusted weights for the logistic regression analyses.

Next, we compared 1-year changes in each biomarker between case and control participants, stratified by intervention group. We also compared 1-year changes among case participants in the intensive group versus those in the standard group. Although comparing control participants between intervention groups was not part of our prespecified analytic plan, these data were included for completeness. We examined 1-year changes by modeling the difference (1-year minus baseline) in log2-transformed biomarker concentrations by using linear mixed-effects models, adjusting for baseline SBP and both linear and quadratic terms for log2-transformed urinary creatinine concentrations. To account for the matched study design, we included case–control pair ID as a random effect and adjusted for the matching variables (age, race, sex, and eGFR). Only participants with complete data for case–control pairs were included in these analyses, which resulted in varying sample sizes across the biomarkers. Predicted (least-squares) means of the change in biomarker and centile 95% CIs were back transformed to estimate the mean ratio of 1-year to baseline levels. Associated Wald tests for differences in the predicted mean changes were used to test significance. The mean changes in each biomarker and the comparisons between groups were presented graphically for ease of communication. We used an interaction term to evaluate whether relative biomarker changes between case and control participants were statistically different between the intervention and standard groups.

Role of the Funding Source

This ancillary study was funded by the National Institute for Diabetes and Digestive and Kidney Diseases (NIDDK). The funding source had no involvement in study design, analysis, or production of the final manuscript.

RESULTS

After control participants were matched to incident CKD case participants on age, sex, race, baseline eGFR, and randomization group, additional baseline characteristics and cardiovascular risk factors were well balanced between the case participants and their matched controls (Table 1). The only exception was baseline SBP, which was significantly higher among the case than the control participants within both intervention groups. At 1 year after randomization, persons with incident CKD in both intervention groups had significantly higher serum creatinine concentrations and lower eGFRs than their respective matched controls. In addition, persons in the intensive group were prescribed greater numbers of antihypertensive medications, including angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers, at 1 year than those in the standard group. Within the intensive group, the CKD case participants were prescribed significantly more antihypertensive medications and had significantly lower diastolic blood pressures at 1 year than their matched controls.

At baseline, the 9 kidney biomarkers were only weakly intercorrelated (Appendix Table 3, available at Annals.org); moderate correlations were observed for only 2 biomarker pairs ($\alpha_{2\text{M}}$ and $\beta_{2\text{M}}$ [$r = 0.53$], and KIM-1 and MCP-1 [$r = 0.49$]), whereas the other pairwise comparisons showed weak associations. We evaluated the association between baseline biomarker concentrations and incident CKD case status, adjusting for baseline SBP and urinary creatinine levels (Table 2). Higher ACR and urinary KIM-1 and MCP-1 concentrations were each significantly associated with greater odds of incident CKD. These results were not affected by reweighting of the matched control participants to the broader cohort of non-case participants (Appendix Table 4, available at Annals.org). In stratifying by intervention group, we observed similar effect sizes in each group, although the associations were not statistically significant in the standard group (Appendix Table 5, available at Annals.org).

The 1-year biomarker concentrations among case and control participants in each intervention group are presented in Appendix Table 6 (available at Annals.org). We compared the 1-year relative changes in each biomarker between case and control participants and found that persons with incident CKD in the intensive group had relative declines in ACR, IL-18, YKL-40, and uromodulin that differed significantly from the relative changes in matched control participants (Figure). In the intensive group, the 1-year relative changes in KIM-1, NGAL, $\beta_{2\text{M}}$, and $\alpha_{2\text{M}}$ levels did not differ significantly between case and control participants, and MCP-1 rel-
atively increased in case participants. In the standard group, no significant differences in 1-year relative changes were observed between case and control participants for any biomarker. We tested for interactions comparing the case–control differences between the 2 intervention groups and found none to be statistically significant (Appendix Table 7, available at Annals.org).

At 1 year, the case participants in the standard group had higher values of all 9 biomarkers compared with those in the intensive group, but the difference was statistically significant only for YKL-40 ($P = 0.01$) (Appendix Table 6). We compared the 1-year relative changes in each biomarker between CKD case participants in the intensive group and those in the standard group, adjusting for baseline SBP and urinary creatinine levels, and found significant differences for ACR, $\beta_2$M, $\alpha_1$M, YKL-40, and uromodulin (Figure). Among case participants, values of all 5 of these biomarkers were lower at 1 year in the intensive group and were either higher or unchanged in the standard group.
To determine whether use of renin-angiotensin-aldosterone system inhibitors influenced the decrease in ACR, we stratified the participants in the intensive group by users (n = 90) and nonusers (n = 19) of angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers during follow-up until CKD diagnosis. The median reduction in ACR was near unity among these 2 groups (−33% [interquartile range, −66% to 25%] vs. −46% [interquartile range, −86% to 41%], respectively). Among case participants in the standard group, the change in ACR differed substantially by use of these medications: −16% (interquartile range, −68% to 44%) among 23 users versus 85% (interquartile range, 54% to 159%) among 10 nonusers.

**DISCUSSION**

In this case–control study nested within a trial of persons with hypertension and without CKD at baseline, we used a diverse panel of urinary biomarkers to characterize intrinsic kidney damage among incident CKD case participants in the setting of intensive SBP reduction to less than 120 mm Hg. Our findings demonstrate that despite substantial eGFR declines in participants who developed CKD during SPRINT’s first year, incident CKD cases in the setting of intensive blood pressure lowering were not characterized by intrinsic kidney damage; rather, these participants had less injury overall than matched control participants without CKD. In contrast, incident CKD case participants in the standard study group had relatively higher levels of 5 of the 9 biomarkers we evaluated compared with those in the intensive group. These data support the notion that eGFR declines in the setting of intensive blood pressure lowering are generally manifestations of benign changes in renal blood flow.

Although participants did not have clinically diagnosed CKD at baseline, we found that baseline urinary ACR and urinary KIM-1 and MCP-1 concentrations were associated with incident CKD during follow-up. Compared with the baseline characteristics of control participants, those of matched participants with future incident CKD otherwise were distinguished only by higher SBP. These findings suggest that urinary biomarkers may identify persons with subclinical kidney injury who may be at increased risk for subsequent eGFR changes. These findings are consistent with studies in other settings that reported associations of ACR, KIM-1, and MCP-1 with incident CKD and kidney function decline (15–17).

Our comparisons of 1-year biomarker changes also are consistent with previous clinical trials reporting that eGFR declines have divergent associations with cardiovascular disease and mortality, depending on whether they occur during intensive versus standard SBP management (18–22). For example, a post hoc analysis of the SPS3 (Secondary Prevention of Small Subcortical Strokes) trial found that early eGFR declines within the intensive SBP reduction group were not associated with adverse cardiovascular outcomes, in contrast to eGFR declines within the standard care group, which portended greater cardiovascular risk (23). Likewise, analyses of the MDRD and AASK (African American Study of Kidney Disease and Hypertension) trials found that participants randomly assigned to more intensive SBP lowering had initial elevations in creatinine levels, but lower long-term mortality risk, relative to participants assigned to less intensive management (24, 25). These investigators hypothesized that blood pressure treatment decreases renal blood flow and reduces hydrostatic pressure gradients across the glomerular capillaries, in turn benignly decreasing creatinine clearance and eGFR. Building on these findings, our results suggest that blood pressure lowering may even alleviate hypertensive kidney injury, regardless of changes in serum creatinine levels.

Although we measured a panel of biomarkers to broadly characterize kidney damage, highlighting the unique physiologic domains these biomarkers represent is important. For example, serum albumin, α₁M,
and $\beta_2M$ are systemic proteins filtered at the glomerulus and reabsorbed by the proximal tubules. Urinary concentrations of these proteins decreased significantly in the case participants in the intensive group versus those in the standard group at 1 year (26–28). These relative decreases among case participants in the intensive group may be a direct reflection of reduced renal blood flow and glomerular filtration of these proteins in the setting of intensive blood pressure lowering, independent of renin-angiotensin-aldosterone system inhibitor use. In contrast, the relative elevations among case participants in the standard group may represent impaired tubular absorption of these proteins, a manifestation of true intrinsic kidney damage.

The other 6 biomarkers are produced largely within the kidney and released into urine, and 2 of these biomarkers differed significantly in the comparison.

**Figure.** One-year percentage changes in levels of 9 urinary biomarkers among incident CKD case participants (black bars) and matched control participants without CKD (gray bars), stratified by randomization group, in SPRINT.
Biomarkers of Kidney Damage and Incident CKD

ORIGINAL RESEARCH

sons of case participants between the 2 randomization groups: YKL-40 and uromodulin decreased in the case participants in the intensive group and remained unaltered or increased in those in the standard group. YKL-40 is produced largely by kidney tubular cells and signifies kidney tubular injury and repair (29, 30). The relative decreases in YKL-40 levels suggest that participants with incident CKD in the setting of intensive blood pressure lowering had less tubular damage than matched control participants and less than case participants in the standard group. However, this pattern was not observed for other traditional markers of tubular injury (for example, IL-18, KIM-1, NGAL, and MCP-1).

The relative decreases in uromodulin levels among case participants in the intensive group that differed significantly from elevations among case participants in the standard group were unexpected. Uromodulin, which is produced in the thick ascending limb of the loop of Henle and the distal tubule, is believed to protect against CKD. When measured at a single time point, higher uromodulin levels were associated with less CKD progression in a previous study (31), although baseline uromodulin levels were not associated with the odds of incident CKD in our current study. We expected to observe relative elevations in uromodulin levels among case participants in the intensive group. However, dynamic changes in uromodulin were not evaluated in previous studies. A possibility exists that lower renal blood flow may lead to a decreased requirement for uromodulin production or secretion. Nonetheless, we acknowledge that this finding may be discrepant with our overall hypotheses. Future studies are necessary to examine the dynamic changes of uromodulin in response to treatments that influence kidney health and its association with outcomes.

Strengths of this study include the matched case-control design in a randomized trial setting, which minimized potential confounding. The SPRINT study involved 102 centers across the United States and Puerto Rico, closely followed the participants, and collected creatinine measurements and longitudinal urine samples frequently, which provided a unique opportunity to investigate kidney changes in the context of intensive blood pressure reduction.

We also acknowledge several important limitations. Although the biomarker results exhibit a consistent pattern overall, we cannot explain the biological mechanisms of some of the changes specifically. For example, KIM-1 and NGAL were significantly increased to a similar magnitude in comparisons of case versus control participants. We are uncertain why these biomarkers would increase during follow-up, and to our knowledge, no previous study measured them repeatedly in a similar cohort. In addition, our study lacked power to compare case and control participants who received standard therapy, because only 34 incident CKD cases occurred in this group. This may explain the absence of significant differences in baseline biomarkers in case participants in the standard group as well as significant differences in the 1-year changes between case and control participants in this group. Because we measured biomarkers only at baseline and at year 1, we do not have biomarker concentrations from the precise time of CKD diagnosis. Most incident CKD end points occurred after the 1-year biomarker measurements; thus, concentrations may have been different if measured at the time of incident CKD diagnosis. However, the mean eGFR decline at 1 year was significantly greater among case than control participants in the intensive group (20 vs. 4 mL/min/1.73 m²) and in the standard group (16 vs. 0 mL/min/1.73 m²), so the eGFR had already decreased substantially among the incident CKD case participants at the time of biomarker measurement. If the substantial eGFR declines found among case participants in the intervention group had been associated with intrinsic kidney injury, we should have detected elevations in biomarker concentrations at 1 year. Finally, our findings may not be generalizable to all persons with hypertension, particularly those with diabetes or proteinuria greater than 1 g/d, who were excluded from SPRINT.

Two important and distinct roles for urinary biomarkers emerge from our findings: identifying persons susceptible to CKD by using the baseline concentrations and using changes in the biomarkers to evaluate longitudinal changes in kidney health. The biomarkers that provided baseline prediction of CKD, a potential proxy of kidney reserve, were not the same as those that reflect responses to blood pressure changes. An eventual biomarker panel in clinical care will warrant a collection of proteins that achieve both these objectives. Future work should investigate whether urinary biomarkers can prognosticate and distinguish persons with true tubular injury accompanying eGFR changes in CKD, similar to the use of these biomarkers in acute kidney injury (32, 33).

In conclusion, the perception of a tradeoff between cardiovascular benefits and kidney harms during intensive blood pressure lowering may be misguided. We found that participants with incident CKD in the setting of intensive SBP treatment did not have elevations in kidney damage biomarkers in the first year of treatment; instead, they had relative declines in several biomarkers compared with both matched control and CKD case participants in the standard group. These findings suggest that eGFR reductions observed in the setting of intensive blood pressure lowering are mostly hemodynamic in nature, even among persons who may be inappropriately labeled as having a new diagnosis of CKD. We also demonstrate the limitations of serum creatinine and the potential utility of urinary biomarkers for monitoring kidney health during hypertension treatment; when changes in renal blood flow may confound the clinical interpretation of changes in serum creatinine levels. Ultimately, these findings, in conjunction with the lower cardiovascular disease and mortality risk reported in SPRINT, should reassure clinicians who embark on evidence-based intensive blood pressure lowering for their patients.
From San Francisco Veterans Affairs Medical Center and University of California, San Francisco, California (W.R.Z., M.G.S.); Wake Forest School of Medicine, Winston-Salem, North Carolina (T.E.C.); University of California, San Diego, La Jolla, and Imperial Valley Family Care Medical Group, El Centro, California (R.M.); University of Utah, Salt Lake City, Utah (A.K.C.); University of Colorado, Aurora, Colorado (M.C.); University of Minnesota, Minneapolis, Minnesota (P.D.); Tufts Medical Center, Boston, Massachusetts (M.J.S.); Johns Hopkins University School of Medicine, Baltimore, Maryland (C.R.P.); and University of California, San Diego, La Jolla, and Veterans Affairs San Diego Healthcare System, San Diego, California (J.H.I.).

Note: All components of the SPRINT study protocol were designed and implemented by the investigators. The investiga- tive team collected, analyzed, and interpreted the data. All aspects of manuscript writing and revision were carried out by the coauthors.

Disclaimer: The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health (NIH), the U.S. Department of Veterans Affairs, or the U.S. government.

Acknowledgment: The SPRINT investigators thank Takeda Pharmaceuticals International for contributing study medica- tion (azilsartan and azilsartan combined with chlorthalidone).

Grant Support: This ancillary study was supported by grant R01DK098234 from the NIDDK to Drs. Ix and Shlipak. Mr. Zhang is supported by grant TL1TR001871 from NIH/National Center for Advancing Translational Sciences (NCATS). The SPRINT study is funded by the NIH, including the National Heart, Lung, and Blood Institute (NHLBI); NIDDK; National Institute on Aging; and National Institute of Neurological Disorders and Stroke, under contracts HHSN268200900040C, HHSN268200900046C, HHSN268200900047C, HHSN268200900048C, and HHSN268200900049C and Inter-Agency Agreement A1HL-13-002-001. It also is partly supported with resources and use of facilities through the U.S. Department of Veterans Affairs. The SPRINT investigators are supported by the following NCATS-funded Clinical and Translational Science Awards: Case Western Reserve University, UL1TR000439; Ohio State University, UL1RR025755; University of Pennsylvania, UL1RR024134 and UL1TR000003; Boston University, UL1TR025771; Stanford University, UL1TR000093; Tufts University, UL1RR025752, UL1TR000073 and UL1TR001064; University of Illinois, UL1TR000050; University of Pittsburgh, UL1TR000005; University of Texas Southwestern, 9U54TR00017-06; University of Utah, UL1TR000105-05; Vanderbilt University, UL1TR000445; George Washington University, UL1TR000075; University of California, Davis, UL1TR000002; University of Florida, UL1TR000064; University of Michigan, UL1TR000433; Tulane University, Centers of Biomedical Research Excellence Award P30GM103337, National Institute of General Medical Sciences; and Wake Forest University, UL1TR001420.

Disclosures: Mr. Craven reports grant support from NIH/ NHLBI/NIDDK during the conduct of the study. Dr. Cheung reports grant support from NIH during the conduct of the study. Dr. Sarnak serves on the steering committee for an ana- mia treatment study funded by Akebia; funds for his involve- ment are paid to Tufts Medical Center. Dr. Shlipak reports grant support from Cricket Health and TAI Diagnostics out- side the submitted work. Dr. Ix reports grant support from NIDDK during the conduct of the study. Authors not named here have disclosed no conflicts of interest. Disclosures can also be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M18-1037.

Reproducible Research Statement: Study protocol: See the Supplement (available at Annals.org). Statistical code: Available from Mr. Craven (e-mail, tcraven@wakehealth.edu). Data set: Available from SPRINT Coordinating Center (e-mail, pnance@wakehealth.edu).

Corresponding Author: Michael G. Shlipak, MD, MPH, Kidney Health Research Collaborative, 4150 Clement Street, Building 2, Room 145, San Francisco, CA 94121; e-mail, michael.shlipak.ucsf.edu.

Current author addresses and author contributions are available at Annals.org.

References
Biomarkers of Kidney Damage and Incident CKD


Current Author Addresses: Mr. Zhang and Dr. Shlipak: Kidney Health Research Collaborative, 4150 Clement Street, Building 2, Room 145, San Francisco, CA 94121.
Mr. Craven: Wake Forest University Health Sciences, Department of Biostatistical Sciences, Medical Center Boulevard, Room 4303, Winston-Salem, NC 27157.
Dr. Malhotra: University of California, San Diego, 9500 Gilman Drive, #9111H, La Jolla, CA 92039.
Dr. Cheung: Division of Nephrology and Hypertension, 30 North 1900 East, Room 4R312, Salt Lake City, UT 84132.
Dr. Chonchol: University of Colorado Hospital, 12605 East 16th Avenue, Aurora, CO 80045.
Dr. Drawz: Division of Renal Diseases and Hypertension, 717 Delaware Street Southeast, Suite 353, MMC 1932, Minneapolis, MN 55414.
Dr. Sarnak: Division of Nephrology, Tufts Medical Center, 800 Washington Street, Box 391, Boston, MA 02111.
Dr. Parikh: Johns Hopkins University School of Medicine, 1830 East Monument Street, Suite 416, Baltimore, MD 21287.
Dr. Ix: University of California, San Diego, 3350 La Jolla Village Drive, Mail Code 111-H, San Diego, CA 92161.

Author Contributions: Conception and design: M. Chonchol, P. Drawz, C.R. Parikh, M.G. Shlipak, J.H. Ix.
Drafting of the article: W.R. Zhang, T.E. Craven, R. Malhotra, M.G. Shlipak.
Provision of study materials or patients: A.K. Cheung, J.H. Ix.
Statistical expertise: T.E. Craven, J.H. Ix.
Administrative, technical, or logistic support: W.R. Zhang, A.K. Cheung, M. Chonchol, P. Drawz.

APPENDIX: SPRINT Research Group Members

Study Leadership

Paul Whelton (Chair), Karen C. Johnson (Vice-Chair), Joni Snyder (Project Officer)
Program Office: NIH, Bethesda, Maryland
Diane Bild (Project Scientist), Denise Bonds (Project Scientist), Nakela Cook (Project Scientist), Jeffrey Cutler (Project Scientist), Lawrence Fine (Project Scientist), Peter Kaufmann (Project Scientist), Paul Kimmel (Project Scientist), Lenore Launer (Project Scientist), Claudia Moy (Project Scientist), William Riley (Project Scientist), Laurie Ryan (Project Scientist), Joni Snyder (Project Officer), Eser Tolunay (Project Scientist), Song Yang (Biostatistician)

SPRINT Drug Distribution Center: Veterans Affairs (VA) Cooperative Studies Program Clinical Research Pharmacy Coordinating Center

Robert Ringer (PI), Brandi Dillard (Coordinator), Norbert Archibeque (Coordinator), Stuart Warren (Co-I), Mike Sather (PI), James Pontzer (Programmer), Zach Taylor (Programmer).

SPRINT ECG Reading Center: Epidemiological Cardiology Research Center (EPICARE), Winston-Salem, North Carolina

Elsayed Z. Soliman (PI), Zhu-Ming Zhang (Co-I), Yabing Li (Coordinator), Chuck Campbell (Coordinator), Susan Hensley (Coordinator), Julie Hu (Coordina-
tor), Lisa Keasler (Coordinator), Mary Barr (Coordinating Director), Tonya Taylor (Coordinator).

**SPRINT MRI Reading Center: University of Pennsylvania, Philadelphia, Pennsylvania**

R. Nick Bryan (PI), Christos Davatzikos (Co-I), Ilya Nasarallah (Co-I), Lisa Desiderio (Project Manager), Mark Elliott (MRI Physicist), Ari Borthakur (MRI Physicist), Harsha Battapady (Data Analyst), Guray Erus (Postdoctoral Fellow), Alex Smith (Postdoctoral Fellow), Ze Wang (Research Associate), Jimit Doshi (Data Analyst).

**SPRINT Clinical Center Networks (CCNs): Case Western Reserve University, Cleveland, Ohio**

Jackson T. Wright Jr. (CCN PI), Mahboob Rahman (CCN Co-PI), Alan J. Lerner (CCN MIND PI), Mahboob Rahman (CCN Co-PI), Carolyn Still (CCN Project Manager, Co-I), Alan Wiggers (CCN Co-PI), Sara Zamanian, (CCN Assistant Project Manager), Alberta Bee (former CCN Assistant Project Manager), Renee Dancie (former CCN Project Manager).

**Ohio Network**

*Cleveland Clinic Foundation, Cleveland, Ohio*

George Thomas (PI), Martin Schreiber Jr. (Co-I), Sankar Dass Navaneethan (Co-I), John Hickner (Co-I), Michael Lioudis (Co-I), Michelle Lard (Co-I), Susan Marczewski (former Coordinator), Jennifer Maraschky (Coordinator), Martha Colman (former Coordinator) Andrea Aaby (Coordinator), Stacey Payne (Coordinator), Melanie Ramos (Coordinator), Carol Horner (former Coordinator).

*Louis Stokes Cleveland VA Medical Center, Cleveland, Ohio*

Mahboob Rahman (PI), Paul Drawz (Co-I), Pratibha P. Raghavendra (Co-I), Scott Ober (Co-I), Ronda Mourad (Co-I), Muralidhar Pallaki (Co-I), Peter Russo (Co-I), Pratibha Raghavendra (Co-I), Pual Fantauzzo (Co-I), Lisa Tucker (Coordinator), Bill Schwing (Coordinator).

*MetroHealth Medical Center, Cleveland, Ohio*

John R. Sedor (PI), Edward J. Horwitz (Co-PI), Jeffrey R. Schelling (Co-I), John F. O’Toole (Co-I), Lisa Humbert (Coordinator), Wendy Tutolo (Coordinator).

*Northeast Ohio Neighborhood Health Center, Cleveland, Ohio*

Suzanne White (PI), Alisha Gay (former Co-I), Walter Clark Jr. (former PI), Robin Hughes (Coordinator).

*University Hospital Case Medical Center, Cleveland, Ohio*

Mirela Dobre (PI), Jackson T. Wright Jr. (Co-I), Carolyn H. Still (Co-I), Alberta Bee (Coordinator), Monique Williams (Coordinator).

*The Ohio State University Medical Center, Division of Nephrology and Hypertension, Columbus, Ohio*

Udayan Bhatt (PI), Lee Hebert (former PI), Anil Agarwal (Co-PI), Melissa Brown Murphy (Coordinator), Nicole Ford (former Coordinator), Cynthia Stratton (Coordinator), Jody Baxter (former Coordinator), Alicia A. Lykins (former Coordinator), Alison McKinley Neal (former Coordinator), Leena Hirmath (former Coordinator).

*The Ohio State University Medical Center, Division of Endocrine, Diabetes, and Metabolism, Columbus, Ohio*

Osei Kwame (PI), Kyaw Soe (Co-I), William F. Miser (former Co-PI), Colleen Sagrilla (Coordinator), Jan Johnston (Coordinator), Amber Anaya (Coordinator), Ashley Mintos (Coordinator), Angel A. Howell (Coordinator), Kelly Rogers (former Coordinator), Sara Taylor (former Co-I).

*University Hospitals Landerbrook Health Center, Mayfield Heights, Ohio*

Donald Ebersbacher (PI), Lucy Long (Coordinator), Beth Bednarchik (Coordinator).

*University Hospitals Glenridge Office Park, North Royalton, Ohio*

Alan Wiggers (PI), Lucy Long (Coordinator).

*University Hospitals Suburban Health, Cleveland, Ohio*

Adrian Schnall (PI), Jonathan Smith (Coordinator), Lori Peysa (Coordinator), Lori Peysa (Coordinator), Beth Bednarchik (Coordinator), Lisa Leach (Coordinator), Megan Tribout (Coordinator).

*University Hospitals Otis Moss Jr. Health Center, Cleveland, Ohio*

Carla Harwell (PI), Pinkie Ellington (Coordinator).

*State University of New York Downstate Medical Center, New York, New York*

Mary Ann Banerji (PI), Pranav Ghody (Co-I), Melissa Vahideh Rambaud (Coordinator).

*University of Pennsylvania, Philadelphia, Pennsylvania*

Raymond Townsend (PI), Debbie Cohen (Co-I), Yonghong Huan (Co-I), Mark Duckworth (former Coordinator), Virginia Ford (Coordinator), Juliet Leshner (Coordinator), Ann Davison (Coordinator), Sarah Vander Veen (Coordinator).

*Temple University, Philadelphia, Pennsylvania*

Crystal A. Gadegbeku (PI), Avi Gillespie (Co-I), Anuradha Paranjape (Co-I), Sandra Amoroso (Coordinating Director).
nator), Zoe Pfeffer (Coordinator), Sally B. Quinn (Coordinator).

Tulane University, New Orleans, Louisiana
Jiang He (PI), Jing Chen (Co-I), Eva Lustigova (Coordinator), Erin Malone (Coordinator).

Ochsner Clinic Foundation, New Orleans, Louisiana
Marie Krousel-Wood (PI), Richard Deichmann (Co-I), Patricia Ronney (Co-I), Susan Muery (Coordinator), Donnalee Trapani (Coordinator).

Wake Forest University Health Sciences, Winston-Salem, North Carolina
Michael Rocco (PI), David Goff (former Co-PI), Carlos Rodriguez (Co-I), Laura Coker (Co-I), Amret Hawfield (Co-I), Joseph Yeboah (Co-I), Lenore Crago (CCN Coordinator), John Summers (CCN Coordinator), Anita Hege (MIND Coordinator).

Southeast Network
Georgia Regents University, Augusta, Georgia
Matt Diamond (PI), Laura Mulloy (PI), Marcela Hodges (Coordinator), Michelle Collins (Coordinator), Charlene Weathers (Coordinator), Heather Anderson (former Coordinator), Emily Stone (former Coordinator), Walida Walker (former Coordinator).

Carolinas Medical Center, Charlotte, North Carolina
Andrew McWilliams (PI), Michael Dulin (Co-I), Lindsay Kuhn (Co-PI), Susan Standridge (Coordinator), Lindsay Lowe (Coordinator), Kelly Everett (Coordinator), Kelry Preston (former Coordinator), Susan Norton (former Coordinator), Silena Gaines (former Coordinator).

University of South Carolina, Columbia, South Carolina
Ali A. Rizvi (PI), Andrew W. Sides (Co-PI), Diamond Herbert (Coordinator), Matthew M. Hix (Coordinator), Melanie Whitmire (former Coordinator), Brittany Arnold (former Coordinator), Philip Hutchinson (former Coordinator), Joseph Espiritu (former Coordinator).

Duke University, Durham, North Carolina
Mark Feinglos (PI), Eugene Kovalik (Co-PI), Georgiann Gedon-Lipscomb (Coordinator), Kathryn Evans (Coordinator), Connie Thacker (Coordinator), Ronna Zimmer (Coordinator), Mary Bur (Coordinator), Mary Ann Mason (former Coordinator).

East Carolina University, Greenville, North Carolina
James Powell (PI), Paul Bolin (Co-PI), Junhong Zhang (Co-PI), Mary Pinion (Coordinator), Gail Davis (Coordinator), Winifred Bryant (former Coordinator), Presley Phelps (former Coordinator), Connie Garriss-Sutton (former Coordinator), Beatrice Atkinson (former Coordinator).

University of Miami, Miami, Florida
Gabriele Contreras (PI), Maritza Suarez (Co-PI), Ivonne Schulman (Co-PI), Don Koggan (Coordinator), Jackie Vassallo (Coordinator), Gloria Peruyera (former Coordinator).

Wake Forest Nephrology, Winston-Salem, North Carolina
Michael Rocco (PI), Amret Hawfield (Co-PI), Sheri Whittington (Coordinator), Cassandra Bethea (former Coordinator), Laura Gilliam (former Coordinator).

Wake Forest Downtown Health Plaza, Winston-Salem, North Carolina
Carolyn Pedley (PI), Geraldine Zurek (Coordinator), Miriam Baird (Coordinator), Charles Herring (PharmD), Mary Martha Smoak (former Coordinator).

Wake Forest Geriatrics, Winston-Salem, North Carolina
Julie Williams (PI), Samantha Rogers (Co-PI), Lindsay Gordon (Coordinator), Erin Kennedy (Coordinator), Beverly Belle (Coordinator), Jessica McCorkle-Doomy (former Coordinator), Jonathan Adams (former Coordinator), Dana Chamberlain (former Coordinator).

University of South Florida, Tampa, Florida
Ramon Lopez (PI), Juris Janavs (Coordinator).

Emory University, Atlanta, Georgia
Frederic Rahbari-Oskou (PI), Arlene Chapman (former PI), Allen Dollar (former Co-PI), Olubunmi Williams (Coordinator), Yoosun Han (former Coordinator).

Mayo Clinic Jacksonville, Jacksonville, Florida
William Haley (PI), Peter Fitzpatrick (Co-PI), Joseph Blackshear (Co-PI), Brian Shapiro (Co-PI), Anna Harrell (Coordinator), Arta Palaj (Coordinator), Katelyn Henderson (Coordinator), Ashley Johnson (former Coordinator), Heath Gonzalez (former Coordinator), Jermaine Robinson (former Coordinator).

Miami VA, Miami, Florida
Leonardo Tamariz (PI), Ivonne Schulman (Co-PI), Jennifer Denizard (Coordinator), Rody Barakat (former Coordinator), Dhurga Krishnamoorthy (former Coordinator).

Pennington Biomedical Research, Baton Rouge, Louisiana
Frank Greenway (PI), Ron Monce (Co-I), Timothy Church (former PI), Chelsea Hendrick (Coordinator),
Aimee Yoches (Coordinator), Leigehanne Sones (Coordinator), Markee Baltazar (former Coordinator).

Morehouse School of Medicine, Atlanta, Georgia
  Priscilla Pemu (PI), Connie Jones (Coordinator), Derrick Akpalu (Coordinator).

University of Utah, Salt Lake City, Utah
  Alfred K. Cheung (PI), Srinivasa Beddhu (Co-PI), Gordon Chelune (MIND Co-I), Jeffrey Childs (Associate Director of Operations), Lisa Gren (Director of Operations), Anne Randall (CCN Coordinator).

Utah Network
  Boston University Medical Center, Boston, Massachusetts
  Laura Dember (PI), Denise Soares (Coordinator).

Henry Ford Hospital, Detroit, Michigan
  Jerry Yee (PI), Kausik Umanath (Co-PI), Naima Ogletree (Sub-I), Schawana Thaxton (Sub-I), Karen Campana (Coordinator), Dayna Sheldon (Coordinator), Krista MacArthur (Coordinator).

Intermountain Health Care, Salt Lake City, Utah
  J. Brent Muhlestein (PI), Nathan Allred (Co-I), Brian Clements (Co-I), Ritesh Dhar (Co-I), Kent Meredith (Co-I), Viet Le (Co-I), Edward Miner (Co-I), James Orford (Co-I), Erik R. Riessen (Co-I), Ben Chisum (Coordinator), Kevin Johnson (Coordinator), Dixie Peeler (Coordinator).

Stanford University, Palo Alto, California
  Glenn Chertow (PI), Manju Tamura (Co-PI), Tara Chang (Co-I), Kevin Erickson (Co-I), Jenny Shen (Co-I), Randall S. Stafford (Co-I), Gregory Zaharchuk (Co-I), Margaret Del Cid (Coordinator), Michelle Dentinger (Coordinator), Jennifer Sabino (Coordinator), Rukmani Sahay (Coordinator), Ekaterina (Katie) Telminova (Coordinator).

Tufts Medical Center, Boston Massachusetts
  Daniel E. Weiner (PI), Mark Sarnak (Co-I), Lily Chan (Coordinator), Amanda Civiletto (Coordinator), Alyson Heath (Coordinator), Amy Kantor (Coordinator), Priyanka Jain (Coordinator), Bethany Kirkpatrick (Coordinator), Andrew Well (Coordinator), Barry Yuen (Coordinator).

University of Colorado, Denver, Denver, Colorado
  Michel Chonchol (PI), Beverly Farmer (Coordinator), Heather Farmer (Coordinator), Carol Greenwald (Coordinator), Mikaela Malaczewski (Coordinator).

University of Illinois, Chicago, Chicago, Illinois
  James Lash (PI), Anna Porter (Co-I), Ana Ricardo (Co-I), Robert T. Rosman (Co-I), Janet Cohan (Coordinator), Nieves Lopez Barrera (Coordinator), Daniel Meslar (Coordinator), Patricia Meslar (Coordinator).

University of Pittsburgh, Pittsburgh, Pennsylvania
  Margaret (Molly) Conroy (PI), Mark Unruh (PI), Rachel Hess (Co-PI), Manisha Jham (Co-I), Holly Thomas (Co-I), Pam Fazio (Coordinator), Elle Klixbull (Coordinator), Melissa Komlos-Weimer (Coordinator), LeeAnne Mandich (Coordinator), Tina Vita (Coordinator).

University of Texas Southwestern, Dallas, Texas
  Robert Toto (PI), Peter Van Buren (Co-I), Julia Iriig (Co-I), Martha Cruz (Coordinator), Tammy Lightfoot (Coordinator), Nancy Wang (Coordinator), Lori Webster (Coordinator).

University of Utah, Salt Lake City, Utah
  Srinivasa Beddhu (PI), Kalani Raphael (Co-I), Barry Stults (Co-I), Tahir Zaman (Co-I), Debra Simmons (Co-I), Tooran Lavasani (Nurse Practitioner), Rebecca Filipowicz (Senior Research Analyst), Guo Wei (Senior Research Analyst), Gracie Mary Miller (Coordinator), Jenice Harerra (Coordinator), Jeff Christensen (Clinical Research Assistant), Ajay Giri (Clinical Research Assistant), Xiaorui Chen (Graduate Research Assistant), Natalie Anderton (Graduate Research Assistant), Arianna Jensen (Undergraduate Research Assistant).

Vanderbilt University, Nashville, Tennessee
  Julia Lewis (PI), Anna Burgner (Co-I), Jamie P. Dwyer (Co-I), Gerald Schulman (Co-I), Terri Herrud (Coordinator), Ewanda Leavell (Coordinator), Tiffany McCray (Coordinator), Edwina McNeil-Simaan (Coordinator), Munmun Poudel (Coordinator), Malia Reed (Coordinator), Mohammed Saka (Coordinator), Delia Woods (Coordinator), Janice L. Zirkenbach (Coordinator).

George Washington University, Washington DC
  Dominic S. Raj (PI), Scott Cohen (Co-I), Samir Patel (Co-I), Manuel Velasquez (Co-I), Roshti S. Bastian (Coordinator), Akshay Roy-Chaudhury (Coordinator).

University of California, Davis, Sacramento, California
  Thomas Depner (PI), Lorien Dalrymple (Co-I), George Kaysen (Co-I), Susan Anderson (Coordinator).

Salt Lake City VA, Salt Lake City, Utah
  Srinivasa Beddhu (PI), John Nord (Co-I), Debra Simmons (Co-I), Gracie Mary Miller (Coordinator),
Jenice Harerra (Coordinator), Ajay Giri (Clinical Research Assistant).

Veterans Medical Research Foundation, San Diego, California
   Joachim H. Ix (PI), Leonard Goldenstein (Co-PI), Cynthia M. Miracle (Co-I), Nketi Forbang (Coordinator), Maja Mircic (Coordinator), Brenda Thomas (Coordinator), Tiffany Tran (Coordinator).

University of California, Los Angeles, Los Angeles, California
   Anjay Rastogi (PI), Mihae Kim (Sub-PI), Mohamad Rashid (Co-PI), Bianca Lizzarraga (Coordinator), Amy Hocza (Coordinator), Kristine Sarnosyan (Coordinator), Jason Norris (Coordinator), Tushar Sharma (Coordinator), Amanda Chiyo (Coordinator), Eric Bernard (Coordinator), Eleanore Cabrera (Coordinator), Christina Lopez (Coordinator), Susana Nunez (Coordinator), Joseph Riad (Coordinator), Suzanne Schweitzer (Coordinator), Siran Sirop (Coordinator), Sarah Thomas (Coordinator), Lauren Wada (Coordinator).

Loyola University Medical Center, Chicago, Illinois
   Holly Kramer (PI), Vinod Bansal (Co-PI), Corliss E. Taylor (Coordinator).

University of Florida, Gainesville, Florida
   Mark S. Segal (PI), Karen L. Hall (Co-I), Amir Kazory (Co-I), Lesa Gilbert (Coordinator), Linda Owens (Coordinator), Danielle Poulton (Coordinator), Elaine Whidden (Coordinator).

University of Michigan, Ann Arbor, Michigan
   Jocelyn (Jo) Wiggins (PI), Caroline Blaum (PI), Linda Nyquist (Co-I), Lillian Min (Co-I), Tanya Gure (Co-I), Ruth Lewis (Coordinator), Jennifer Mawby (Coordinator), Eileen Robinson (Coordinator).

University of Alabama (UAB), Birmingham, Alabama
   Suzanne Oparil (PI), Cora E. Lewis (Co-PI), Virginia Bradley (MIND Co-I), David Calhoun (Co-I), Stephen Glasser (Co-I), Kim Jenkins (CCN Coordinator), Tom Ramsey (CCN Coordinator).

UAB Network
   Athens Internal Medicine, Athens, Alabama
      Nauman Qureshi (PI), Karen Ferguson (Coordinator), Sumrah Haider (Coordinator), Mandy James (Coordinator), Christy Jones (Coordinator), Kim Renfroe (Coordinator), April Seay (Coordinator), Carrie Weigart (Coordinator).

   UAB Chronic Kidney Disease Clinic, Birmingham, Alabama
      Denyse Thornley-Brown (PI), Dana Rizik (Co-I), Bari Cotton (Coordinator), Meredith Fitz-Gerald (Coordinator), Tiffany Grimes (Coordinator), Carolyn Johnson (Coordinator), Sara Kennedy (Coordinator), Chanel Mason (Coordinator), Lesa Rosato-Burson (Coordinator), Robin Willingham (Coordinator).

   UAB Vascular Biology and Hypertension Clinic, Birmingham, Alabama
      David Calhoun (PI), Eric Judd (Co-I), Tonya Breaux-Shropshire (Coordinator), Felice Cook (Coordinator), Julia Medina (Coordinator), Lama Ghazi (Coordinator), Hemal Bhatt (Coordinator).

   Nephrology Associates, PC, Birmingham, Alabama
      James Lewis (PI), Roman Brantley (Co-I), John Bouliette (Co-I), Jeffrey Glaze (Co-I), Stephanie Hall (Co-I), Nancy Hiott (Co-I), David Thorpe (Co-I), Spencer Boddy (Coordinator), Catherine Mack (Coordinator).

   University of Tennessee Health Science Center, Memphis, Tennessee
      Karen C. Johnson (PI), Catherine Womack (Co-I), Keiko Asao (Co-I), Beate Griffin (Coordinator), Carol Hendrix (Coordinator), Karen Johnson (Coordinator), Lisa Jones (Coordinator), Chelsea Towers (Coordinator).

   Punzi Medical Center and Trinity Hypertension Research, Carrollton, Texas
      Henry Punzi (PI), Kathy Cassidy (Coordinator), Kristin Schumacher (Coordinator).

   Family Care Practice, Fajardo, Puerto Rico
      Carmen Irizarry (PI), Ilma Colon (Coordinator).

   Centro Cardiovascular de Caguas, El Verde, Caguas, Puerto Rico
      Pedro Colon-Ortiz (PI), Pedro J. Colón-Hernández (Co-I), Orlando J. Carrasquillo-Navarro (Co-I), Merari Carrasquillo (Coordinator), Nivea Vazquez (Coordinator).

   Miguel Sosa-Padilla, Private Practice, San Juan, Puerto Rico
      Miguel Sosa-Padilla (PI), Alex Cintron-Pinero (Co-I), Mayra Ayala (Coordinator), Olga Pacheco (Coordinator), Catalina Rivera (Coordinator), Irma Sotomayor-Gonzalez (Coordinator).
Altamira Family Practice and Research Institute Center, San Juan, Puerto Rico
Jamie Claudio (PI), Jose Lazaro (Coordinator), Migdalia Arce (Coordinator), Lourdes Heres (Coordinator), Alba Perez (Coordinator).

Centro Clinico San Patricio, San Juan, Puerto Rico
Jose Tavarez-Valle (PI), Ferlinda Arocho (Coordinator), Mercedes Torres (Coordinator), Melvaliz Vazquez (Coordinator).

University of Massachusetts-Worcester, Worcester, Massachusetts
Gerard P. Aurigemma (PI), Rebecca Takis-Smith (Co-I), Julia Andrieni (Co-I), Noelle Bodkin (Coordinator), Kiran Chaudhary (Coordinator), Paula Hu (Coordinator).

Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey
John Kostis (PI), Nora Cosgrove (Coordinator), Denise Bankowski (Coordinator), Monica Boleyn (Coordinator), Victoria Giresi (Coordinator), Tosha Patel (Coordinator), Erin Squindo (Coordinator), Yan Wu (Coordinator).

University of Mississippi Medical Center CRP, Jackson, Mississippi
Zeb Henson (PI), Marion Wofford (Co-PI), Jessica Lowery (Co-I), Deborah Minor (Co-I), Kimberley Harkins (Co-I), Alexander Auchus (Co-I), Michael Flessner (Co-I), Cathy Adair (Coordinator).

Nashville Medical Group, Nashville, Tennessee
Jordan Asher (PI), Debbie Loope (Coordinator), Reiner Venegas (Coordinator).

New York Irving Pavilion Research, Columbia University, New York, New York
Thomas Bigger (Director), Natalie Bello (Co-PI), Shunichi Homma (Co-PI), Daniel Donovan (Co-PI), Carlos Lopez-Jimenez (Co-I), Amilcar Tirado (Coordinator).

New York Irving Pavilion Research Unit—CTSA Satellite, Columbia University, New York, New York
Thomas Bigger (Director), Natalie Bello (Co-PI), Shunichi Homma (Co-PI), Asqual Getaneh (Co-PI), Rocky Tang (Coordinator), Sabrina Durant (Coordinator).

Clinical Cardiovascular Research Lab for the Elderly, Columbia University, New York, New York
Thomas Bigger (Director), Natalie Bello (Co-PI), Shunichi Homma (Co-PI), Mathew Maurer (Co-PI), Sergio Teruya (Research Scientist), Stephen Helmke (Coordinator), Julissa Alvarez (Research Assistant).

Medical University of South Carolina Nephrology, Charleston, South Carolina
Ruth Campbell (PI), Roberto Pisoni (Co-I), Rachel Sturdivant (Co-I), Deborah Brooks (Co-I), Caroline Counts (Coordinator), Vickie Hunt (Coordinator), Lori Spillers (Coordinator).

Great Lakes Medical Research, Westfield, New York
Donald Brautigam (PI), Timothy Kitchen (Co-I), Timothy Gorman (Co-I), Jessica Sayers (Coordinator), Sarah Button (Coordinator), June Chiarot (Coordinator), Rosemary Fischer (Coordinator), Melissa Lyon (Coordinator), Maria Resnick (Coordinator), Nicole Hodges (Research Assistant), Jennifer Ferreira (Site Manager).

Memphis VA Medical Center, Memphis, Tennessee
William Cushman (PI), Barry Wall (Co-I), Linda Nichols (MIND PI), Robert Burns (MIND Consultant), Jennifer Martindale-Adams (MIND Consultant), Dan Berlowitz (Economic and Health-Related Quality-of-Life Consultant), Elizabeth Clark (CCN Coordinator), Sandy Walsh (CCN Coordinator) Terry Geraci (CCN Coordinator), Carol Huff (Budget Analyst), Linda Shaw (CCN Research Assistant).

VA Network
New Mexico VA Healthcare System, Albuquerque, New Mexico
Karen Servilla (PI), Darlene Vigil (Co-I), Terry Barrett (Coordinator).

Atlanta VA Medical Center, Atlanta, Georgia
Mary Ellen Sweeney (PI), Rebecca Johnson (Co-I), Susan McConnell (Co-I), Khadijah Shahid Salles (Co-I), Françoise Watson (Co-I), Cheryl Schenk (Coordinator), Laura Whittington (Coordinator), Maxine Maher (Coordinator).

VA Boston Healthcare System, Jamaica Plain, Massachusetts
Jonathan Williams (PI), Stephen Swartz (PI), Paul Conlin (Co-I), George Alexis (Coordinator), Rebecca Lamkin (Coordinator), Patti Underwood (Coordinator), Helen Gomes (Coordinator).

James J. Peters VA Medical Center, Bronx, New York
Clive Rosendorff (PI), Stephen Atlas (Co-I), Saadat Khan (Co-I), Waddy Gonzalez (Co-I), Samih Barcham (Co-I), Lawrence Kwon (Co-I), Matar Matar (Coordinator), Anwar Adhami (Coordinator)

Ralph H. Johnson VA Medical Center, Charleston, South Carolina
Roberto Pisoni (PI), Jan Basile (PI), Joseph John (PI), Deborah Ham (Coordinator), Hadi Baig (Coordinator).
Dayton VA Medical Center, Dayton, Ohio
Mohammed Saklayen (PI), Jason Yap (Co-I), Helen Neff (Coordinator), Carol Miller (Coordinator), Ling Zheng-Phelan (Coordinator).

John D. Dingell VA Medical Center, Detroit, Michigan
Saib Gappy (PI), Shiva Rau (Co-I), Arathi Raman (Co-I), Vicki Berchou (Coordinator), Elizabeth Jones (Coordinator), Erin Olgren (Coordinator), Cynthia Marbury (Coordinator).

VA New Jersey Healthcare System, East Orange, New Jersey
Michael Yudd (PI), Sithiporn Sastrasinh (PI), Jennine Michaud (Co-I), Jessica Fiore (Coordinator), Marianne Kutza (Coordinator).

Malcom Randall VA Medical Center, Gainesville, Florida
Ronald Shorr (PI), Rattana Mount (Co-I), Helen Dunn (Coordinator), Susan Stinson (Coordinator), Jessica Hunter (Coordinator).

Michael E. DeBakey VA Medical Center, Houston, Texas
Addison Taylor (PI), Jeffery Bates (Co-I), Catherine Anderson (Coordinator).

G.V. (Sonny) Montgomery VA Medical Center, Jackson, Mississippi
Kent Kirchner (PI), Jodi Stubbs (Co-I), Ardell Hinton (Co-I), Anita (Kaye) Spencer (Coordinator).

Kansas City VA Medical Center, Kansas City, Missouri
Santosh Sharma (PI), Thomas Wiegmann (PI), Smita Mehta (Coordinator).

John L. McClellan Memorial Veterans Hospital, Little Rock, Arkansas
Michelle Krause (PI), Kate Dishongh (Coordinator).

Memphis VA Medical Center, Memphis, Tennessee
Barry Wall (PI), Richard Childress (Co-I), William Cushman (Co-I), Geeta Gyamlini (Co-I), Atossa Niakan (Co-I), Cathy Thompson (Co-I), Janelle Moody (Coordinator), Carolyn Gresham (Coordinator).

Clement J. Zablocki VA Medical Center, Milwaukee, Wisconsin
Jeffrey Whittle (PI), Gary Barnas (Co-I), Dawn Wolfram (Co-I), Heidi Cortese (Coordinator), Jonette Johnson (Coordinator).

Nashville VA Medical Center/Tennessee Valley Healthcare System—Geriatric Research, Education and Clinical Center, Nashville, Tennessee
Christianne Roumie (PI), Adriana Hung (Co-I), Jennifer Wharton (Coordinator), Kurt Niesner (Coordinator).

Lois Katz (PI), Elizabeth Richardson (Coordinator), George Brock (Coordinator).

Northport VA Medical Center, Northport, New York
Joanne Holland (PI), Troy Dixon (PI), Athena Zias (PI), Christine Spiller (Coordinator).

Phoenix VA Healthcare System, Phoenix, Arizona
Penelope Baker (PI), James Felicetta (PI), Shakaib Rehman (Co-I), Kelli Bingham (Coordinator).

Portland VA Medical Center, Portland, Oregon
Suzanne Watnick (PI), David Cohen (PI), Jessica Weiss (Co-I), Tera Johnston (Coordinator).

St. Louis VA Healthcare System, St. Louis, Missouri
Stephen Giddings (PI), Hala Yamout (PI), Andrew Klein (PI), Caroline Rowe (Co-I), Kristin Vargo (Coordinator), Kristi Waidmann (Coordinator).

Washington, DC, VA Medical Center, Washington, DC
Vasilios Papademetriou (PI), Jean Pierre Elkhoury (Co-I), Barbara Gregory (Coordinator), Susan Amodeo (Coordinator), Mary Bloom (Coordinator).

West Los Angeles VA Healthcare Center/Greater Los Angeles Healthcare System, Los Angeles, California
Dalia Goldfarb-Waysman (PI), Richard Treger (PI), Mehran Kashefi (Co-I), Christina Huang (Co-PI), Karen Knibloe (Coordinator).

Minneapolis VA Medical Center, Minneapolis, Minnesota
Areef Ishani (PI), Yelena Slinin (Co-I), Christine Olney (Coordinator), Jacqueline Rust (Coordinator).

Audie L. Murphy Memorial Veterans Hospital—South Texas Veterans Healthcare System, San Antonio, Texas
Paolo Fanti (PI), Christopher Dyer (PI), Shweta Bansal (Co-I), Monica Dunnam (Co-I), Lih-Lan Hu (Coordinator), Perla Zarate-Abbott (Coordinator).
### Appendix Table 1. Urinary Biomarker Assay Information for MSD Multiplex Panels

<table>
<thead>
<tr>
<th>Assays</th>
<th>Dilution</th>
<th>Standard Range</th>
<th>Minimum Detectable Concentration</th>
<th>Manufacturer-Defined &quot;Normal&quot; Range</th>
</tr>
</thead>
<tbody>
<tr>
<td>Albumin</td>
<td>1:251</td>
<td>0.0488-200 ng/mL</td>
<td>0.141 ng/mL</td>
<td>Undetectable-48 757 ng/mL</td>
</tr>
<tr>
<td>IL-18</td>
<td>1:10</td>
<td>0.64-10 000 pg/mL</td>
<td>0.161 pg/mL</td>
<td>NA</td>
</tr>
<tr>
<td>KIM-1</td>
<td>1:10</td>
<td>1.28-20 000 pg/mL</td>
<td>0.19 pg/mL</td>
<td>NA</td>
</tr>
<tr>
<td>NGAL</td>
<td>1:251</td>
<td>0.0024-10.00 ng/mL</td>
<td>0.0029 ng/mL</td>
<td>4.20-225.00 ng/mL</td>
</tr>
<tr>
<td>MCP-1</td>
<td>1:10</td>
<td>0.64-10 000 pg/mL</td>
<td>0.071 pg/mL</td>
<td>1.95-1173 pg/mL</td>
</tr>
<tr>
<td>YKL-40</td>
<td>1:10</td>
<td>3.20-50 000 pg/mL</td>
<td>0.346 pg/mL</td>
<td>NA</td>
</tr>
<tr>
<td>β₂M</td>
<td>1:251</td>
<td>0.0049-20.00 ng/mL</td>
<td>0.0061 ng/mL</td>
<td>38.00-1130.00 ng/mL</td>
</tr>
<tr>
<td>Uromodulin</td>
<td>1:251</td>
<td>0.0244-100.00 ng/mL</td>
<td>0.026 ng/mL</td>
<td>347.00-7846.00 ng/mL</td>
</tr>
</tbody>
</table>

β₂M = β₂-microglobulin; CKD = chronic kidney disease; IL-18 = interleukin-18; KIM-1 = kidney injury molecule-1; MCP-1 = monocyte chemoattractant protein-1; MSD = Meso Scale Discovery; NA = not available; NGAL = neutrophil gelatinase-associated lipocalin; YKL-40 = anti–chitinase-3-like protein 1.

### Appendix Table 2. Urinary Biomarker Assay Information for Non-MSD Assays

<table>
<thead>
<tr>
<th>Assay</th>
<th>Instrument</th>
<th>Method</th>
<th>Detectable Range</th>
</tr>
</thead>
<tbody>
<tr>
<td>α₁M, Creatinine</td>
<td>BN II nephelometer</td>
<td>Immunochemical</td>
<td>5-80 mg/L</td>
</tr>
<tr>
<td>β₂M, Creatinine</td>
<td>Cobas c 311</td>
<td>Enzymatic</td>
<td>1.1-610 mg/dL</td>
</tr>
</tbody>
</table>

α₁M = α₁-microglobulin; MSD = Meso Scale Discovery.

### Appendix Table 3. Spearman Correlations of Baseline Biomarker Concentrations

<table>
<thead>
<tr>
<th>Variable</th>
<th>ACR</th>
<th>α₁M</th>
<th>β₂M</th>
<th>Uromodulin</th>
<th>IL-18</th>
<th>KIM-1</th>
<th>MCP-1</th>
<th>YKL-40</th>
<th>NGAL</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACR</td>
<td>1</td>
<td>0.36</td>
<td>0.27</td>
<td>0.01</td>
<td>0.23</td>
<td>0.25</td>
<td>0.27</td>
<td>0.21</td>
<td>0.19</td>
</tr>
<tr>
<td>α₁M</td>
<td>0.36</td>
<td>1</td>
<td>0.53</td>
<td>0.16</td>
<td>0.21</td>
<td>0.03</td>
<td>0.05</td>
<td>0.28</td>
<td>0.19</td>
</tr>
<tr>
<td>β₂M</td>
<td>0.27</td>
<td>0.53</td>
<td>1</td>
<td>0.21</td>
<td>0.1</td>
<td>0.08</td>
<td>0.07</td>
<td>0.28</td>
<td>0.19</td>
</tr>
<tr>
<td>Uromodulin</td>
<td>0.01</td>
<td>0.16</td>
<td>0.21</td>
<td>0.21</td>
<td>0.09</td>
<td>0.08</td>
<td>0.07</td>
<td>0.28</td>
<td>0.28</td>
</tr>
<tr>
<td>IL-18</td>
<td>0.23</td>
<td>0.21</td>
<td>0.08</td>
<td>0.09</td>
<td>–0.08</td>
<td>–0.003</td>
<td>–0.01</td>
<td>–0.04</td>
<td>0.36</td>
</tr>
<tr>
<td>KIM-1</td>
<td>0.25</td>
<td>0.03</td>
<td>0.08</td>
<td>0.08</td>
<td>–0.003</td>
<td>0.23</td>
<td>0.24</td>
<td>0.49</td>
<td>0.36</td>
</tr>
<tr>
<td>MCP-1</td>
<td>0.27</td>
<td>0.05</td>
<td>0.07</td>
<td>0.07</td>
<td>–0.01</td>
<td>0.24</td>
<td>0.24</td>
<td>0.49</td>
<td>0.24</td>
</tr>
<tr>
<td>YKL-40</td>
<td>0.21</td>
<td>0.08</td>
<td>0.28</td>
<td>0.28</td>
<td>–0.04</td>
<td>0.36</td>
<td>0.36</td>
<td>0.11</td>
<td>0.17</td>
</tr>
<tr>
<td>NGAL</td>
<td>0.19</td>
<td>0.03</td>
<td>0.19</td>
<td>0.19</td>
<td>0.08</td>
<td>0.41</td>
<td>0.41</td>
<td>0.21</td>
<td>0.20</td>
</tr>
</tbody>
</table>

ACR = albumin–creatinine ratio; α₁M = α₁-microglobulin; β₂M = β₂-microglobulin; IL-18 = interleukin-18; KIM-1 = kidney injury molecule-1; MCP-1 = monocyte chemoattractant protein-1; NGAL = neutrophil gelatinase-associated lipocalin; YKL-40 = anti–chitinase-3-like protein 1.

### Appendix Table 4. Baseline Biomarker Concentrations Among Incident CKD Case Participants and Matched Control Participants in Both Randomization Groups of SPRINT Combined: Comparison of Results of Unweighted and Weighted LR Analyses

<table>
<thead>
<tr>
<th>Biomarker</th>
<th>Pairs, n</th>
<th>Unweighted LR Analysis*</th>
<th>Weighted LR Analysis</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>OR (95% CI)†</td>
<td>P Value</td>
</tr>
<tr>
<td>ACR, mg/g</td>
<td>150</td>
<td>1.50 (1.14-1.98)</td>
<td>0.004</td>
</tr>
<tr>
<td>IL-18, pg/mL</td>
<td>158</td>
<td>1.30 (0.93-1.79)</td>
<td>0.12</td>
</tr>
<tr>
<td>NGAL, mg/mL</td>
<td>157</td>
<td>0.96 (0.71-1.30)</td>
<td>0.80</td>
</tr>
<tr>
<td>MCP-1, pg/mL</td>
<td>158</td>
<td>1.70 (1.13-2.56)</td>
<td>0.012</td>
</tr>
<tr>
<td>YKL-40, pg/mL</td>
<td>158</td>
<td>1.18 (0.90-1.56)</td>
<td>0.23</td>
</tr>
<tr>
<td>β₂M, ng/mL</td>
<td>154</td>
<td>0.95 (0.74-1.22)</td>
<td>0.68</td>
</tr>
<tr>
<td>α₁M, mg/L</td>
<td>157</td>
<td>1.18 (0.90-1.56)</td>
<td>0.23</td>
</tr>
<tr>
<td>Uromodulin, μg/mL</td>
<td>157</td>
<td>1.04 (0.77-1.40)</td>
<td>0.80</td>
</tr>
</tbody>
</table>

ACR = albumin–creatinine ratio; α₁M = α₁-microglobulin; β₂M = β₂-microglobulin; CKD = chronic kidney disease; IL-18 = interleukin-18; KIM-1 = kidney injury molecule-1; LR = logistic regression; MCP-1 = monocyte chemoattractant protein-1; NGAL = neutrophil gelatinase-associated lipocalin; OR = odds ratio; SPRINT = Systolic Blood Pressure Intervention Trial; YKL-40 = anti–chitinase-3-like protein 1.

* See Table 2.
† Per SD increase in log₂-transformed biomarker concentrations. All models except for ACR adjust for log₂-transformed urinary creatinine concentrations. All models adjust for baseline systolic blood pressure.
### Appendix Table 5. Comparison of Baseline Biomarker Concentrations Among Incident CKD Case Participants and Matched Control Participants in SPRINT, by Randomization Group

<table>
<thead>
<tr>
<th>Biomarker</th>
<th>Intensive BP Group</th>
<th>Standard BP Group</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Geometric Mean (±SE)</td>
<td>OR (95% CI)*</td>
</tr>
<tr>
<td>ACR, mg/g</td>
<td>118</td>
<td>19.3 ± 2.4</td>
</tr>
<tr>
<td>IL-18, pg/mL</td>
<td>124</td>
<td>37.0 ± 3.3</td>
</tr>
<tr>
<td>KIM-1, pg/mL</td>
<td>124</td>
<td>621.3 ± 72.4</td>
</tr>
<tr>
<td>NGAL, ng/mL</td>
<td>124</td>
<td>25.3 ± 2.7</td>
</tr>
<tr>
<td>MCP-1, pg/mL</td>
<td>124</td>
<td>163.3 ± 15.2</td>
</tr>
<tr>
<td>YKL-40, pg/mL</td>
<td>124</td>
<td>641.6 ± 68.6</td>
</tr>
<tr>
<td>β2M, ng/mL</td>
<td>121</td>
<td>78.5 ± 9.5</td>
</tr>
<tr>
<td>α1M, mg/L</td>
<td>124</td>
<td>10.3 ± 0.70</td>
</tr>
</tbody>
</table>

ACR = albumin–creatinine ratio; α1M = α1-microglobulin; β2M = β2-microglobulin; BP = blood pressure; CKD = chronic kidney disease; IL-18 = interleukin-18; KIM-1 = kidney injury molecule-1; MCP-1 = monocyte chemoattractant protein-1; NGAL = neutrophil gelatinase-associated lipocalin; OR = odds ratio; SPRINT = Systolic Blood Pressure Intervention Trial; YKL-40 = anti–chitinase-3-like protein 1.

* Based on SD increase in log2-transformed biomarker concentrations. All models except those for ACR adjust for log2-transformed urinary creatinine concentrations. All models adjust for baseline systolic BP.

### Appendix Table 6. One-Year Biomarker Concentrations Among Incident CKD Case Participants and Matched Control Participants in SPRINT, Overall and by Randomization Group

<table>
<thead>
<tr>
<th>Biomarker</th>
<th>Intensive BP Group</th>
<th>Standard BP Group</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Geometric Mean (±SE)</td>
<td>OR (95% CI)*</td>
</tr>
<tr>
<td>ACR, mg/g</td>
<td>99</td>
<td>11.2 ± 1.3</td>
</tr>
<tr>
<td>IL-18, pg/mL</td>
<td>121</td>
<td>33.6 ± 2.9</td>
</tr>
<tr>
<td>KIM-1, pg/mL</td>
<td>121</td>
<td>819.2 ± 88.3</td>
</tr>
<tr>
<td>NGAL, ng/mL</td>
<td>120</td>
<td>32.4 ± 3.5</td>
</tr>
<tr>
<td>MCP-1, pg/mL</td>
<td>121</td>
<td>244.8 ± 23.5</td>
</tr>
<tr>
<td>YKL-40, pg/mL</td>
<td>121</td>
<td>427.1 ± 59.3</td>
</tr>
<tr>
<td>β2M, ng/mL</td>
<td>110</td>
<td>56.5 ± 9.0</td>
</tr>
<tr>
<td>α1M, mg/L</td>
<td>120</td>
<td>4.14 ± 0.64</td>
</tr>
<tr>
<td>Uromodulin, μg/mL</td>
<td>119</td>
<td>8.4 ± 0.54</td>
</tr>
</tbody>
</table>

ACR = albumin–creatinine ratio; α1M = α1-microglobulin; β2M = β2-microglobulin; BP = blood pressure; CKD = chronic kidney disease; IL-18 = interleukin-18; KIM-1 = kidney injury molecule-1; MCP-1 = monocyte chemoattractant protein-1; NGAL = neutrophil gelatinase-associated lipocalin; OR = odds ratio; SPRINT = Systolic Blood Pressure Intervention Trial; YKL-40 = anti–chitinase-3-like protein 1.

* Based on SD increase in log2-transformed biomarker concentrations. All models except those for ACR adjust for log2-transformed urinary creatinine concentrations. All models adjust for baseline systolic BP.
### Appendix Table 7. Comparisons of 1-Year Changes in Biomarker Concentrations Among Incident CKD Case Participants and Matched Control Participants in SPRINT, by Randomization Group

<table>
<thead>
<tr>
<th>Biomarker</th>
<th>Intensive Group</th>
<th>Standard Group</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Case Participants</td>
<td>Control Participants</td>
<td>Case Participants</td>
</tr>
<tr>
<td>ACR</td>
<td>99</td>
<td>−41 (−52 to −27)</td>
<td>−20 (−34 to −11)</td>
</tr>
<tr>
<td>IL-18</td>
<td>121</td>
<td>−14 (−25 to −2)</td>
<td>5 (−8 to 20)</td>
</tr>
<tr>
<td>KIM-1</td>
<td>121</td>
<td>26 (10 to 44)</td>
<td>16 (2 to 33)</td>
</tr>
<tr>
<td>NGAL</td>
<td>120</td>
<td>23 (2 to 50)</td>
<td>25 (3 to 51)</td>
</tr>
<tr>
<td>MCP-1</td>
<td>121</td>
<td>39 (20 to 61)</td>
<td>13 (−2 to 31)</td>
</tr>
<tr>
<td>YKL-40</td>
<td>121</td>
<td>−40 (−54 to −24)</td>
<td>−18 (−36 to 5)</td>
</tr>
<tr>
<td>α1M</td>
<td>120</td>
<td>−20 (−39 to 6)</td>
<td>−36 (−51 to −16)</td>
</tr>
<tr>
<td>Uromodulin</td>
<td>119</td>
<td>−23 (−34 to −11)</td>
<td>10 (−6 to 28)</td>
</tr>
</tbody>
</table>

ACR = albumin–creatinine ratio; α1M = α1-microglobulin; β2M = β2-microglobulin; CKD = chronic kidney disease; IL-18 = interleukin-18; KIM-1 = kidney injury molecule-1; MCP-1 = monocyte chemoattractant protein-1; NGAL = neutrophil gelatinase-associated lipocalin; SPRINT = Systolic Blood Pressure Intervention Trial; YKL-40 = anti–chitinase-3-like protein 1.

* Changes estimated from linear mixed models with log2 (biomarker) as the outcome. All models except those for ACR adjust for log2-transformed urinary creatinine concentrations. All models adjust for baseline systolic blood pressure.
A small subset of people manifests significant increases in their serum creatinine when blood pressure (BP) is reduced to guideline levels. In this issue of the journal, Collard et al.1 evaluate whether the extent of increase in serum creatinine affected the combined end point of all-cause mortality, major cardiovascular events, and renal outcomes in the ACCORD-BP trial (Action to Control Cardiovascular Risk in Diabetes Blood Pressure). Before we discuss this study, it is essential to understand why this creatinine increase after BP reduction occurs.

The kidney is a regulatory organ driven by BP and can autoregulate its internal pressure within a certain range of systemic BPs between 90 and 180 mm Hg when the kidney is healthy.2 However, during disease, responses can become maladaptive. This maladaptive autoregulatory response manifests itself as more substantial than expected increases in serum creatinine when substantial reductions in BP occur. These increase in serum creatinine, however, are generally not in the range of when substantial reductions in BP occur. The kidney is a regulatory organ driven by BP and can autoregulate its internal pressure within a certain range of systemic BPs between 90 and 180 mm Hg when the kidney is healthy.2 However, during disease, responses can become maladaptive. This maladaptive autoregulatory response manifests itself as more substantial than expected increases in serum creatinine when substantial reductions in BP occur. These increase in serum creatinine, however, are generally not in the range of acute kidney injury (AKI), that is, >50% increases from the baseline, but can be as high as 30% to 35% after BP reduction.1

Given that the dysfunction of autoregulation plays a significant part in allowing changes in creatinine to occur it is essential to understand the provenance of this problem. The most common contributors of impaired autoregulation are antihypertensive medications specifically, calcium antagonists and loop diuretics with partial impairment by renin-angiotensin system (RAS) inhibitors.4 Most patients with diabetes mellitus or chronic kidney disease (CKD) require multiple medications—from at least 2 different classes—to achieve lower BP goals per guidelines thus, exposing some patients to increases in serum creatinine. Poor vascular compliance, identified clinically by pulse pressures of >70 mm Hg, is associated with impaired intrarenal flow, in part, related to lower levels of nitric oxide and associated with reduced kidney function.5 Moreover, tubuloglomerular feedback is also not fully functional when kidney function is reduced.6 Hence, normal myogenic reflexes needed to maintain glomerular filtration rate are reduced. Thus, there are many reasons to expect more significant changes in serum creatinine in people with more advanced CKD or preexisting vascular disease.

Taken together, these changes in the physiological function of the kidney explain why the increment in serum creatinine decline is related to the magnitude of systolic BP reduction and is magnified by RAS blockers. Hence, it would be misleading and inappropriate to view a hemodynamic resetting of kidney function as injury.

Many large epidemiological studies, as well as some smaller studies, demonstrate that increases in serum creatinine up to 30%, within a few weeks after initiation or intensification of antihypertensive therapy, are not associated with adverse renal outcomes or faster declines in kidney function.7,8 The renal outcome defined by Collard et al.1 of changes in serum creatinine in the context of predefined cardiovascular outcomes in ACCORD-BP was not a predefined outcome in the initial ACCORD-BP trial, but one created by the authors. The renal outcome was defined as an increase in serum creatinine to ≥3.3 mg/dL in the absence of an acute reversible cause, renal transplantation or dialysis initiation. In each group, the extent of BP lowering was related to the increment in serum creatinine increase. Furthermore, the number of subjects with an increase in serum creatinine of <10%, 10% to 30%, and >30% from baseline to 4 months were related to the composite cardiorenal outcome using a proportional hazards model. The authors report that the cardiorenal outcome was not dependent on an increase in serum creatinine concentration irrespective of the group. Therefore, they suggest that an increase in serum creatinine can be ignored when intensifying antihypertensive therapy. These are critically important observations and support earlier systematic reviews documenting similar observations.7–9

There are many strengths and some weaknesses of this article. Strengthens of the article include its uniqueness to antihypertensive therapy, are not associated with the initial ACCORD-BP trial and
second, there are no data on whether antihypertensive therapy was reduced in response to a robust increase in serum creatinine. Changes in medication or dose may have influenced the outcome interpretation.

Collard et al. make several important points worth emphasizing. First, the reduction in BP from baseline to 4 months was strongly related to the increase in serum creatinine. Second, the increase in serum creatinine concentration to >30% was more strongly related to an increase in all-cause mortality and cardiovascular mortality in the intensive BP reduction group only. Conversely, similar increases in serum creatinine were more strongly related to an increase in renal outcomes in the standard BP reduction group. In our opinion, it seems that competing risks of renal failure and all-cause mortality neutralized the overall effect of >30% increase in serum creatinine concentration with the composite cardiorenal outcome.

The notion that competing risks are operative has been demonstrated previously in a cohort of patients with CKD, where a lower systolic BP is a promoter of all-cause mortality but a protector from end-stage renal disease.11 Since the authors do not report whether antihypertensive therapy was reduced in response to an increase in serum creatinine, we cannot, even in an observational data set analyzed from a randomized trial, begin to answer the question of whether antihypertensive therapy could be reduced or not.

Given the limitations of these analyses, it is prudent to stick to what experts consider to be best practice. If a patient has an increase in serum creatinine of >30% after initiation or intensification of antihypertensive therapy, one should evaluate the circumstances surrounding these changes. They should assess whether this change was indeed kidney injury, or a hemodynamic change reflecting underlying volume depletion or related to poor vascular compliance or intrarenal vascular disease. Thus, for each case the clinical risks and benefits of continuing or reducing antihypertensive therapy should be performed.

Multiple reports attest to the safety of limited, increases in serum creatinine of up to 30% after BP is reduced significantly, regardless of RAS blocker use.7,8,11,14 The earliest review of this topic noted a strong association between increases in serum creatinine of up to 30% that stabilize within 2 months of starting a RAS inhibitor and correlate with long-term renal preservation.7 This relationship holds for people with serum creatinine values of >1.4 mg/dL (>124 mmol/L). The only reason to reduce RAS blockade in this study was hyperkalemia.7 A 10-year follow-up study in almost 19,000 patients with stage 3b CKD notes a 0.2% incidence of serum creatinine increases by 50% or more associated with RAS blockers.8 None developed renal failure requiring dialysis and dehydration, infection and heart failure were the most common settings, where this elevation occurred. Lastly, a population-based cohort study using electronic health records in Denmark examined >122,000 patients and noted 2078 (1.7%) with creatinine increases of 30% or more.15 These people were at higher risk for cardiovascular events and death, however a higher proportion was elderly, had preexisting cardiorenal comorbidity, and used nonsteroidal anti-inflammatory drugs, loop or potassium-sparing diuretics, all of which predispose to serum creatinine elevations with BP lowering as discussed earlier.

The most recent prospective trial to shed light on renal and cardiovascular outcomes associated with serum creatinine elevations is the SPRINT (Systolic Blood Pressure Intervention Trial), a multicenter, randomized study with 9361 participants that demonstrated reduced cardiovascular events in the group randomized to a BP <120 mm Hg compared with 140 mm Hg in patients with CKD.16 Rocco et al.16 evaluated the incidence of AKI among the entire SPRINT cohort. There were 179 participants with AKI events in the intensive arm and 109 in the standard arm (3.8% versus 2.3%; hazard ratio, 1.64; 95% CI, 1.30–2.10; P<0.001).14 Of 288 participants with an AKI event, 248 (86.1%) had a single AKI event with 58.5% a mild stage 1 AKI. Complete or partial resolution of AKI was seen for 169 (90.4%) of 187 AKI events in the intensive arm. Moreover, when markers for AKI were examined in SPRINT there was no evidence that any established marker for kidney injury was increased, hence, this was a hemodynamic change.17

In short, data from clinical trials indicate that people with CKD garner a cardiovascular risk reduction at BP levels <130/80 mm Hg, despite increases in serum creatinine of ≤30% above baseline. In most cases, this is a hemodynamic effect that can be mitigated by ensuring the patient is not taking agents that affect renal autoregulation and ensuring the patient is volume replete. In most cases, the easiest way to assess volume is measure orthostatic drop in systolic arterial pressure.

Despite the availability of observational data in thousands of patients, population effects often are insufficient to guide treatment decisions in individuals. Medicine is involved, and complex conditions will require multifactorial decision-making that can best be made by well-informed physicians. What we learn from the ACCORD analysis is that a rise in serum creatinine of >30% is a marker of future nonrenal morbidity and mortality. What we do about it is a matter of clinical judgment.

Sources of Funding

R. Agarwal has received National Institutes of Health funding.

Disclosures

G. Bakris—Member scientific advisory board or consultant for Merck, Janssen, Novo Nordisk, Astra Zeneca, Boehringer Ingelheim, Bayer, Relypsa, Reata. Steering Committee Member-Janssen, Bayer (principal investigator-renal outcome trial). R. Agarwal—Member data safety monitoring committees: Astra Zeneca, Ironwood Pharmaceuticals. Member steering committees of randomized trials: Akebia, Bayer, Janssen, Glaxo Smith Cline, Relypsa, Sanofi, and Genzyme US Companies. Member adjudication committees: Bayer, Boehringer Ingelheim, Janssen. Member scientific advisory board or consultant: Celgene, Daiichi Sankyo, Inc, Eli Lilly, Relypsa, Reata, Takeda Pharmaceuticals, USA, and ZS Pharma.

References

Diabetic nephropathy is a highly frequent complication in patients with diabetes mellitus, an independent predictor of cardiovascular mortality and morbidity, and the leading cause of renal failure in most developed countries. Blood pressure (BP)-lowering treatment is effective in reducing the risk of diabetic nephropathy and for the prevention of renal function decline. However, intensive BP-lowering treatment is also associated with a decrease in renal function and the composite end point consisting of all-cause mortality, major cardiovascular events, and renal failure. Patients were stratified into 3 groups according to serum creatinine increase between baseline and 4 months (<10%, 10%–30%, >30%). A total of 4733 patients, aged 62.2 years, 52% men with a mean estimated glomerular filtration rate 81.5 mL/min per 1.73 m² were included. Follow-up was available for 4446 patients, 2231 were randomized to intensive and 2215 to standard therapy. Kaplan-Meier analysis showed no association between a serum creatinine increase and the composite end point in the intensive (P=0.20) and the standard treatment group (P=0.17). After adjusting for possible confounders, a >30% serum creatinine increase was associated with a higher risk of clinical adverse outcomes in both treatment groups, but to a similar extent. These data suggest that a >30% serum creatinine increase that coincides with lower blood pressure values should not directly lead to a reduction in antihypertensive medication in patients with type 2 diabetes mellitus. Clinical Trial Registration—URL: http://www.clinicaltrials.gov. Unique identifier: NCT00000620.

**Abstract**—Lowering blood pressure may affect renal function. Current guidelines state that reducing antihypertensive therapy should be considered in patients with a >30% serum creatinine increase after initiation of antihypertensive therapy. We examined the association between a serum creatinine increase and adverse clinical outcomes in the ACCORD-BP trial (Action to Control Cardiovascular Risk in Diabetes Blood Pressure), were patients with type 2 diabetes mellitus were randomized to intensive (target systolic blood pressure <120 mm Hg) and standard antihypertensive (<140 mm Hg) treatment. The primary outcome was a combined end point consisting of all-cause mortality, major cardiovascular events, and renal failure. Patients were stratified into 3 groups according to serum creatinine increase between baseline and 4 months (<10%, 10%–30%, >30%). A total of 4733 patients, aged 62.2 years, 52% men with a mean estimated glomerular filtration rate 81.5 mL/min per 1.73 m² were included. Follow-up was available for 4446 patients, 2231 were randomized to intensive and 2215 to standard therapy. Kaplan-Meier analysis showed no association between a serum creatinine increase and the composite end point in the intensive (P=0.20) and the standard treatment group (P=0.17). After adjusting for possible confounders, a >30% serum creatinine increase was associated with a higher risk of clinical adverse outcomes in both treatment groups, but to a similar extent. These data suggest that a >30% serum creatinine increase that coincides with lower blood pressure values should not directly lead to a reduction in antihypertensive medication in patients with type 2 diabetes mellitus.

**Key Words:** blood pressure ■ cardiovascular diseases ■ diabetes mellitus ■ hypertension ■ kidney

**Clinical Trial Registration**—URL: http://www.clinicaltrials.gov. Unique identifier: NCT00000620.

**Hypertension. 2018;72:1337-1344. DOI: 10.1161/HYPERTENSIONAHA.118.11944.** • **Online Data Supplement**

...
and an impaired renal autoregulation. This may pose patients with diabetes mellitus and an increase in serum creatinine at increased risk for adverse clinical outcomes during intensive BP-lowering treatment. The ACCORD-BP trial (Action to Control Cardiovascular Risk in Diabetes Blood Pressure) was a prospective randomized control trial of intensive, a target systolic BP (SBP) <120 mmHg, versus standard (target SBP <140 mmHg) BP-lowering therapy in patients with type 2 diabetes mellitus at high risk for cardiovascular events. Because of its design using different BP-lowering thresholds, the ACCORD study provides a unique opportunity to assess whether the rise in creatinine during BP-lowering treatment is a sign of preexisting renal damage or points toward ischemic nephropathy caused by hypoperfusion. In the present post hoc analysis, we assessed whether the serum creatinine increase during intensive BP-lowering treatment is associated with more adverse clinical outcomes compared with standard therapy.

Methods

Study Design and Patient Eligibility

All data used for this study has been made publicly available at the Biolincc repository and can be requested at https://biolincc.nhlbi.nih.gov/studies/accord/. The ACCORD trial was a randomized control trial conducted from January 2001 to June 2009 at 77 clinical sites in the United States and Canada, which enrolled 10,251 high-risk patients with type 2 diabetes mellitus, who were randomized to either intensive or standard glycemia control. Inclusion ended in 2005. Using a 2 by 2 factorial design a subgroup of 4733 participants was assigned to intensive or standard BP-lowering treatment in the ACCORD-BP trial. ACCORD-BP was designed to have 94% power to detect a 20% reduction in the rate of cardiovascular events in the intensive treatment group. The design, rationale, main results, and safety outcomes of this study have been published elsewhere. Participants were eligible if they had a diagnosis of type 2 diabetes mellitus, had glycated hemoglobin level of 7.5% or more, and were older than 40 years with cardiovascular disease or older than 55 years with anatomic evidence of a substantial amount of atherosclerosis, albuminuria, left ventricular hypertrophy, or at least 2 additional risk factors for cardiovascular disease (dyslipidemia, hypertension, smoking, or obesity). Patients with a serum creatinine level of >1.5 mg/dL were excluded. For inclusion in the BP trial, participants were required to have an SBP between 130 and 180 mmHg with 3 or fewer antihypertensive medications, and a 24-hour protein excretion rate of <1.0 g. This trial was sponsored by the National Heart, Lung and Blood Institute, and the protocol was approved by the institutional review board of each participating center and by an independent review committee of the National Heart, Lung and Blood Institute. The use of the data set for the present analysis was approved by the institutional review board of the Cleveland Clinic and by an independent review committee of the National Heart, Lung and Blood Institute. The use of the data set for the present analysis was approved by the institutional review board of the Cleveland Clinic and by an independent review committee of the National Heart, Lung and Blood Institute. The use of the data set for the present analysis was approved by the institutional review board of the Cleveland Clinic and by an independent review committee of the National Heart, Lung and Blood Institute. The use of the data set for the present analysis was approved by the institutional review board of the Cleveland Clinic and by an independent review committee of the National Heart, Lung and Blood Institute.

Trial Intervention

Participants were randomly assigned to an SBP target of <120 mmHg (intensive treatment group) and an SBP of <140 mmHg (standard treatment group). The allocation was performed centrally using permuted blocks through the study’s website. Participants and physicians were not blinded to treatment strategy. In the intensive treatment group, visits were scheduled once a month for the first 4 months and every 2 months thereafter. In the standard treatment group, visits were in month 1, month 4, and every 4 months thereafter. At each visit, BP mediation could be titrated or switched to reach the target SBP according to the protocol. No specific medication was required and treatment strategies of normal clinical practice could be applied. At each 4-month visit information about study outcome and adverse events were obtained. During the first year, at 4-month intervals, serum creatinine was determined, after this information was obtained on yearly basis. The planned average follow-up was 5.6 years.

Outcomes

For the present analysis, we used the occurrence of adverse clinical outcomes, defined as the composite of the first major cardiovascular event, renal failure, or death because of any cause as primary outcome measure. After the definitions used in ACCORD, a major cardiovascular event was defined as a nonfatal myocardial infarction, a nonfatal stroke or cardiovascular death. Renal failure was defined as renal transplantation, initiation of dialysis, or a rise in serum creatinine >3.3 mg/dL in the absence of an acute reversible cause. Secondary outcomes were the individual components of the primary outcome and the original primary outcome, a major cardiovascular event. All clinical end points were adjudicated by a committee blinded to the treatment assignment.

Statistical Analysis

After previous publications, we chose to stratify patients into 3 groups according to their initial increase in serum creatinine (<10%, 10%–30%, >30%). As initial increase, we used the difference between serum creatinine at baseline and 4 months after randomization. Kaplan-Meier analysis was used to investigate the relation between serum creatinine increase and the primary end point. For the primary and secondary outcomes, Cox-regression analysis was performed. In the crude model, correction was performed for age and sex. An additional term for baseline renal function and baseline SBP was added to the model. Renal function was calculated using the Chronic Kidney Disease Epidemiology Collaboration formula, taking ethnicity into account. Use of medication was determined from the ACCORD-BP trial medication logbook. For the medication and the difference in SBP between baseline and 4 months, the value at 3 or 6 months was used if the value at 4 months was missing. Baseline characteristics were compared between the different strata and treatments groups using the appropriate tests (χ², ANOVA, Kruskal-Wallis). All statistical analyses were conducted with R version 3.4.3 using the Survival version 2.41–3 and Tableone version 0.9.2 packages (Vienna, Austria). The figures were created using Graphpad Prism, version 7 (California).

Results

Baseline Characteristics

A flowchart of participants included in the present analysis is presented in Figure 1. Of the 2362 participants randomized to intensive therapy, 2231 (94.5%) were included in the present analysis. Of the 2371 participants randomized to standard therapy, 2215 (93.4%) were included. Exclusion of participants was because of missing creatinine data. An overview of the baseline characteristics stratified according to treatment group and creatinine increase is given in Table 1. The >30% stratum (n=259; 11.6%) in the intensive treatment group was more than twice as high compared with the standard treatment group (n=122; 5.5%). SBP decreased by 15.9 mmHg in the intensive treatment group and by 6.0 mmHg in the standard treatment group between baseline and 4 months. Compared with subjects without a significant increase in serum creatinine, subjects with a >30% increase had a more profound decrease in SBP. In patients with a <10% increase in serum creatinine, SBP decreased by 12.7 mmHg in the intensive and 4.1 mmHg in the standard treatment group, whereas in those with a >30% increase in creatinine SBP decreased by
25.4 and 16.3 mm Hg, respectively. Subjects with a >30% increase had a higher SBP and diastolic BP at baseline, had a higher estimated glomerular filtration rate (eGFR), a higher Framingham-risk score and higher urinary-to-albumin ratio.

In the intensive treatment group, more patients received an ACE inhibitor or ARB after 4 months than in the standard treatment group, except for the >30% stratum, where the use of ACE inhibitors or ARBs was 94.6% in the intensive and 90.1% in the standard treatment group. At the last study visit, delta SBP with baseline and the use of ACE inhibitors or ARBs remained similar, with a difference of −22.1 and −12.3 mm Hg between the intensive and standard treatment group in the >30% stratum and an 89.6% and 83.6% use of ACE inhibitors or ARBs. The differences in baseline characteristics between the standard and intensive treatment group according to creatinine increase are given in Table I in the online-only Data Supplement.

**Primary and Secondary Outcomes**

After a mean follow-up of 4.9 years, 306 of the subjects developed an event in the intensive treatment group compared with 333 in the standard treatment group. Kaplan-Meier analysis is shown in Figure 2. When stratified to creatinine increase, 161 subjects in the <10% stratum, 105 subjects in the 10%–30% stratum, and 40 subjects in the >30% stratum developed an adverse clinical event in the intensive treatment group, whereas in the standard treatment group, 228 subjects in the <10% stratum, 82 subjects in 10%–30% stratum, and 23 subjects in the >30% stratum had an event. In both the intensive and standard treatment group no significant association was found between an increase in serum creatinine and the primary outcome (P=0.20 for the intensive and P=0.17 for the standard treatment group).

Cox-regression analysis performed to estimate the hazard ratio using the crude model, taking only age and sex into account, yielded the same results and showed no significant association between serum creatinine increase and the primary outcome in both treatment groups (Table 2). In the secondary outcome analysis, a serum creatinine increase was associated with an increased hazard ratio for all-cause mortality and cardiovascular mortality in the intensive treatment group, while in the standard treatment group, no such association was found. However, in the standard treatment group, a >30% serum creatinine increase was associated with an increased hazard ratio for adverse renal events, while in the intensive treatment group, a serum creatinine rise was not associated with adverse renal outcomes. Additional correction for SBP and eGFR at baseline, resulted in a significant association between a >30% serum creatinine increase and adverse clinical outcomes with an adjusted hazard ratio of 1.47 (95% CI, 1.03–2.11) and 1.57 (95% CI, 1.01–2.43) in the intensive and the standard treatment group, while no significant association was present for the 10% to 30% strata.

Further analysis showed that the difference between the crude
and the fully adjusted model was mainly driven by baseline eGFR: a lower eGFR was associated with an increased hazard ratio for adverse clinical outcomes. The results of the Cox-regression using the fully adjusted model for the primary and secondary outcomes are shown in Table II in the online-only Data Supplement. Additional adjustment for allocation to glycemic treatment arm did not materially change the association between the increase in serum creatinine and adverse clinical events.

**Discussion**

Our results show that, when stratified to initial serum creatinine increase, intensive BP treatment does not lead to an increased risk of adverse clinical outcomes compared with standard therapy in patients with type 2 diabetes mellitus. However, in both treatment groups, patients with a >30% serum creatinine increase had a significantly higher risk for adverse outcomes compared with the other strata when adjusted for potential confounders. This suggests that a serum creatinine rise after initiation of antihypertensive therapy is a marker to identify high-risk patients, but that intensive therapy itself does not lead to a further increase in the risk for adverse outcomes. Our results suggest that in patients with diabetes mellitus treatment decisions about the benefits of intensive BP-lowering therapy should not be influenced by an initial serum creatinine increase and that a >30% rise in serum creatinine should alert the clinician to an increased risk for adverse outcomes, but may not necessarily mean that BP-lowering medication needs to be reduced.

Meta-analyses have shown that intensive BP-lowering treatment reduces cardiovascular morbidity and mortality in chronic kidney disease (CKD) patients with and without diabetes mellitus. Therefore, current guidelines emphasize the importance to achieve lower BP goals, but this carries an

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Intensive</th>
<th>Standard</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>No. of subjects</td>
<td>1231</td>
<td>741</td>
<td>259</td>
</tr>
<tr>
<td>Age, mean (SD), y</td>
<td>62.55 (6.61)</td>
<td>62.84 (6.48)</td>
<td>62.82 (6.48)</td>
</tr>
<tr>
<td>Women, n (%)</td>
<td>588 (47.8)</td>
<td>328 (44.3)</td>
<td>138 (53.3)</td>
</tr>
<tr>
<td>Race or ethnic group, n (%)</td>
<td>298 (24.2)</td>
<td>166 (22.4)</td>
<td>56 (21.6)</td>
</tr>
<tr>
<td>SBP, mm Hg, mean (SD)</td>
<td>137.0 (15.4)</td>
<td>140.5 (15.9)</td>
<td>143.8 (18.0)</td>
</tr>
<tr>
<td>DBP, mm Hg, mean (SD)</td>
<td>75.2 (10.2)</td>
<td>76.7 (11.0)</td>
<td>77.5 (10.4)</td>
</tr>
<tr>
<td>History of cardiovascular disease, n (%)</td>
<td>399 (32.4)</td>
<td>257 (34.7)</td>
<td>89 (34.4)</td>
</tr>
<tr>
<td>Framingham 10-y risk of cardiovascular death, median (IQR)*</td>
<td>30.83 (20.81, 43.19)</td>
<td>33.21 (23.11, 46.79)</td>
<td>34.15 (24.87, 46.89)</td>
</tr>
<tr>
<td>Smoker, n (%)</td>
<td>163 (13.2)</td>
<td>105 (14.2)</td>
<td>27 (10.4)</td>
</tr>
<tr>
<td>Body mass index, mean (SD), kg/m²</td>
<td>32.16 (5.59)</td>
<td>32.27 (5.55)</td>
<td>32.61 (5.54)</td>
</tr>
<tr>
<td>Serum creatinine, mg/dL, mean (SD)</td>
<td>0.95 (0.24)</td>
<td>0.84 (0.20)</td>
<td>0.81 (0.25)</td>
</tr>
<tr>
<td>eGFR, mL/min per 1.73 m², mean (SD)</td>
<td>77.79 (17.97)</td>
<td>86.00 (15.38)</td>
<td>86.85 (18.86)</td>
</tr>
<tr>
<td>Ratio of urinary albumin, mg, to creatinine, g, median (IQR)</td>
<td>13.00 (7.00, 37.00)</td>
<td>16.00 (7.50, 49.00)</td>
<td>21.00 (10.00, 84.00)</td>
</tr>
<tr>
<td>Total cholesterol, mg/dL, mean (SD)</td>
<td>193.80 (43.77)</td>
<td>192.76 (45.24)</td>
<td>202.15 (51.43)</td>
</tr>
<tr>
<td>Total HDL, mg/dL, mean (SD)</td>
<td>46.26 (13.15)</td>
<td>46.32 (13.17)</td>
<td>45.05 (13.72)</td>
</tr>
<tr>
<td>Aspirin use, n (%)</td>
<td>674 (55.0)</td>
<td>395 (53.4)</td>
<td>136 (52.7)</td>
</tr>
<tr>
<td>Statin use, n (%)</td>
<td>763 (62.2)</td>
<td>496 (67.0)</td>
<td>168 (65.1)</td>
</tr>
<tr>
<td>ACE inhibitor/ARB use at 4 mo, n (%)</td>
<td>1132 (92.0)</td>
<td>699 (94.3)</td>
<td>245 (94.6)</td>
</tr>
<tr>
<td>ΔSBP baseline and 4 mo, mm Hg, mean (SD)</td>
<td>−12.7 (17.1)</td>
<td>−18.0 (17.8)</td>
<td>−25.4 (18.8)</td>
</tr>
</tbody>
</table>

ACE indicates angiotensin-converting enzyme; ARB, angiotensin receptor blocker; DBP, diastolic blood pressure, eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein; IQR, interquartile range; mo, months; and SBP, systolic BP.

*Only for patients without a history of cardiovascular disease. To convert the values for creatinine to millimoles per liter, multiply by 88.4. To convert the values for cholesterol and HDL to millimoles per liter, multiply by 0.02586. To convert the values for ratio of urinary albumin to creat to mg/mmol, multiply by 0.113.
increased concern of iatrogenic ischemic kidney damage as a result of hypoperfusion.\textsuperscript{8} Evidence that a >30\% rise in creatinine may be harmful is derived from an earlier meta-analysis of randomized trials showing that in patients with preexisting renal insufficiency a serum creatinine increase by >30\% is rare and may point toward hypoperfusion.\textsuperscript{10} In the present post hoc analysis, we found no association between a serum creatinine increase and adverse renal events in the intensive treatment group. In the standard treatment group, however, a >30\% creatinine increase was associated with an increased risk of renal failure. This difference may be explained by the fact that in the standard treatment group other causes for a decrease of renal function than the initiation of antihypertensive therapy were more likely leading to a serum creatinine elevation at higher SBP targets.

A previous analysis of the ONTARGET (Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial) and TRANSCEND trial (Telmisartan Randomized Assessment Study in ACE Intolerant Participants With Cardiovascular Disease) showed an increased risk of adverse renal and cardiovascular outcomes in patients with a >12.7\% decrease in renal function after treatment with an ACE inhibitor or ARB.\textsuperscript{22} A similar finding was also observed in a recent study, which showed that a serum creatinine increase larger than 10\% after initiation of an ACE inhibitor or ARB was associated with increased cardiorenal and mortality risk in a UK primary care population.\textsuperscript{11} The results from the present study confirm these findings by showing that a serum creatinine increase of >30\% is associated with a higher risk of cardiorenal events and death. However, they also illustrate that the increased risk of cardiovascular and renal complications is independent of the attained BP level. This supports the hypothesis that a decline in renal function as a result of antihypertensive therapy should not be interpreted as harmful.

Our findings are in line with an earlier post hoc analysis from the AASK (African American Study of Kidney Disease and Hypertension) and MDRD trial (Modification of Diet in Renal Disease) that examined the effects of intensive BP-lowering treatment in CKD patients without diabetes mellitus. Here, a >20\% decline in renal function during intensive BP therapy was associated with an increased risk for renal failure, while in the standard treatment arm a >5\% decline was already predictive for renal failure.\textsuperscript{17} A post-analysis of the RENAAL trial (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan) found that the initial fall in eGFR after initiation of an ARB in diabetic patients attenuated the decrease in eGFR on the long term, but that the initial change in eGFR was associated with more renal events, the risk being higher in the placebo than the ARB treatment group.\textsuperscript{18} As the target SBP in the RENAAL trial was <140 mm Hg, this finding is in line with the findings of our analysis and those by Ku et al\textsuperscript{17} supporting that an increased risk of adverse renal outcomes is present in patients with a creatinine increase during BP-lowering therapy, but may be protective in the long run.

Our data are in apparent contrast with an earlier analysis of the SPRINT (Systolic Blood Pressure Intervention Trial) and ACCORD trials that reported an increased risk of CKD in patients receiving intensive BP-lowering treatment with and without diabetes mellitus.\textsuperscript{23} However, both in the original and our post hoc analysis of the ACCORD trial, no evidence for an increased risk for renal failure was found in the intensive group compared with the standard group. Because Beddhu et al\textsuperscript{23} defined incident CKD as an eGFR decrease of ≥30\%, it is conceivable that the increase in renal events was merely a reflection of the reversal of hyperfiltration during antihypertensive treatment. Similar, an analysis of acute kidney injury in the SPRINT trial by Rocco et al\textsuperscript{24} showed an increased risk for acute kidney injury in the intensive compared with the standard treatment group. However, acute kidney injury was already defined as a rise >0.3 mg/dL or increase >1.5-fold from baseline. The notion that hyperfiltration is implicated in the serum creatinine rise after antihypertensive treatment is supported by a subgroup analysis in patients with CKD in SPRINT that showed no

![Figure 2. Kaplan-Meier analysis of initial serum creatinine increase versus adverse clinical outcomes, intensive (left) versus standard (right) BP lowering treatment.](http://ahajournals.org)
difference between eGFR reduction after 6 months between the standard and intensive BP targets. The strength of our study is that ACCORD-BP was a large randomized control trial of high-risk patients with type 2 diabetes mellitus who were prone to develop adverse events. This allowed us to determine the contribution of the BP-lowering therapy to the increased risk in patients with an initial serum creatinine increase. The limitation is that this is a post hoc analysis, and the study was not originally powered to answer this question. Most patients received an ACE inhibitor or ARB as part of their BP-lowering treatment, but the choice of medication was left at the discretion of the physician. We, therefore, cannot conclude from our data if the effect observed is primarily the result of lower BP or a result of the use of specific antihypertensive medication. Finally, the ACCORD-BP study only included patients with type 2 diabetes mellitus and although the association between an increase in serum creatinine and increased risk of adverse clinical outcomes is also observed in other populations, effects of intensive BP-lowering treatment may be different.

In conclusion, a >30% serum creatinine increase during BP-lowering treatment in patients with type 2 diabetes mellitus is associated with a higher risk of adverse clinical outcomes compared with standard therapy. Furthermore, there was no association between incidence of renal failure and initial serum creatinine increase in the intensive treatment group. Only during standard therapy, a >30% creatinine increase was associated with a higher risk of adverse clinical outcomes, irrespective of whether standard or intensive BP-lowering therapy was used.

Table 2. Results of Cox-Regression Analysis for Primary and Secondary Outcomes

<table>
<thead>
<tr>
<th>End Point</th>
<th>Intensive (event rate)</th>
<th>HR</th>
<th>L95</th>
<th>U95</th>
<th>P Value</th>
<th>Standard (event rate)</th>
<th>HR</th>
<th>L95</th>
<th>U95</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primary outcome</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;10%</td>
<td>13.1%</td>
<td>1.00</td>
<td></td>
<td></td>
<td></td>
<td>15.4%</td>
<td>1.00</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10%–30%</td>
<td>14.2%</td>
<td>1.16</td>
<td>0.90</td>
<td>1.48</td>
<td>0.25</td>
<td>13.3%</td>
<td>0.91</td>
<td>0.70</td>
<td>1.17</td>
<td>0.45</td>
</tr>
<tr>
<td>&gt;30%</td>
<td>15.4%</td>
<td>1.32</td>
<td>0.94</td>
<td>1.88</td>
<td>0.11</td>
<td>18.9%</td>
<td>1.47</td>
<td>0.96</td>
<td>2.27</td>
<td>0.08</td>
</tr>
<tr>
<td>All-cause mortality</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;10%</td>
<td>4.9%</td>
<td>1.00</td>
<td></td>
<td></td>
<td></td>
<td>5.6%</td>
<td>1.00</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10%–30%</td>
<td>5.8%</td>
<td>1.34</td>
<td>0.90</td>
<td>1.99</td>
<td>0.14</td>
<td>5.7%</td>
<td>1.11</td>
<td>0.75</td>
<td>1.66</td>
<td>0.60</td>
</tr>
<tr>
<td>&gt;30%</td>
<td>9.7%</td>
<td>2.37</td>
<td>1.48</td>
<td>3.80</td>
<td>&lt;0.001</td>
<td>5.7%</td>
<td>1.29</td>
<td>0.59</td>
<td>2.79</td>
<td>0.52</td>
</tr>
<tr>
<td>Nonfatal MI</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;10%</td>
<td>5.5%</td>
<td>1.00</td>
<td></td>
<td></td>
<td></td>
<td>6.6%</td>
<td>1.00</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10%–30%</td>
<td>5.4%</td>
<td>1.02</td>
<td>0.69</td>
<td>1.52</td>
<td>0.91</td>
<td>5.0%</td>
<td>0.81</td>
<td>0.54</td>
<td>1.21</td>
<td>0.30</td>
</tr>
<tr>
<td>&gt;30%</td>
<td>3.5%</td>
<td>0.70</td>
<td>0.35</td>
<td>1.40</td>
<td>0.31</td>
<td>9.0%</td>
<td>1.64</td>
<td>0.87</td>
<td>3.06</td>
<td>0.12</td>
</tr>
<tr>
<td>Nonfatal stroke</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;10%</td>
<td>1.4%</td>
<td>1.00</td>
<td></td>
<td></td>
<td></td>
<td>2.6%</td>
<td>1.00</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10%–30%</td>
<td>1.5%</td>
<td>1.13</td>
<td>0.53</td>
<td>2.42</td>
<td>0.76</td>
<td>2.1%</td>
<td>0.83</td>
<td>0.44</td>
<td>1.57</td>
<td>0.57</td>
</tr>
<tr>
<td>&gt;30%</td>
<td>0.8%</td>
<td>0.62</td>
<td>0.14</td>
<td>2.70</td>
<td>0.53</td>
<td>0.8%</td>
<td>0.35</td>
<td>0.05</td>
<td>2.58</td>
<td>0.31</td>
</tr>
<tr>
<td>Renal failure</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;10%</td>
<td>2.7%</td>
<td>1.00</td>
<td></td>
<td></td>
<td></td>
<td>2.8%</td>
<td>1.00</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10%–30%</td>
<td>2.2%</td>
<td>0.83</td>
<td>0.46</td>
<td>1.52</td>
<td>0.55</td>
<td>1.8%</td>
<td>0.68</td>
<td>0.35</td>
<td>1.32</td>
<td>0.26</td>
</tr>
<tr>
<td>&gt;30%</td>
<td>3.5%</td>
<td>1.47</td>
<td>0.70</td>
<td>3.08</td>
<td>0.31</td>
<td>6.6%</td>
<td>2.62</td>
<td>1.23</td>
<td>5.61</td>
<td>0.013</td>
</tr>
<tr>
<td>CV mortality</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;10%</td>
<td>1.5%</td>
<td>1.00</td>
<td></td>
<td></td>
<td></td>
<td>2.2%</td>
<td>1.00</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10%–30%</td>
<td>3.0%</td>
<td>2.36</td>
<td>1.26</td>
<td>4.43</td>
<td>0.008</td>
<td>1.6%</td>
<td>0.82</td>
<td>0.40</td>
<td>1.67</td>
<td>0.59</td>
</tr>
<tr>
<td>&gt;30%</td>
<td>3.9%</td>
<td>3.16</td>
<td>1.45</td>
<td>6.91</td>
<td>0.004</td>
<td>4.1%</td>
<td>2.46</td>
<td>0.95</td>
<td>6.35</td>
<td>0.06</td>
</tr>
<tr>
<td>Major CV events</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;10%</td>
<td>7.9%</td>
<td>1.00</td>
<td></td>
<td></td>
<td></td>
<td>10.4%</td>
<td>1.00</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10%–30%</td>
<td>9.6%</td>
<td>1.30</td>
<td>0.96</td>
<td>1.77</td>
<td>0.09</td>
<td>8.0%</td>
<td>0.80</td>
<td>0.58</td>
<td>1.10</td>
<td>0.17</td>
</tr>
<tr>
<td>&gt;30%</td>
<td>7.7%</td>
<td>1.09</td>
<td>0.67</td>
<td>1.77</td>
<td>0.73</td>
<td>13.1%</td>
<td>1.51</td>
<td>0.90</td>
<td>2.53</td>
<td>0.12</td>
</tr>
</tbody>
</table>

HR is adjusted for age and sex. L95 and U95 indicate the 95% CI. Less than 10%, 10%–30%, >30% indicate the different creatinine increase strata. CV indicates cardiovascular; HR, hazard ratio; and MI, myocardial infarction.
increase was associated with an increased hazard ratio for renal failure.

**Perspectives**

Current guidelines state that reducing antihypertensive therapy should be considered in patients with a >30% serum creatinine increase. This is based on studies showing that an initial serum creatinine increase during antihypertensive therapy is associated with an increased risk for all-cause mortality, cardiovascular events, and renal failure. This post hoc analysis of the ACCORD-BP trial shows that an initial >30% serum creatinine increase is associated with adverse clinical outcomes, but does not lead to a higher risk of cardiovascular and renal outcomes in patients receiving intensive treatment compared with standard antihypertensive therapy. These data suggest that a serum creatinine increase that coincides with a lower BP should not be interpreted as harmful and lead to a reduction in BP-lowering medication. Further research should focus on whether there is an optimal cutoff value for serum creatinine increase after BP-lowering treatment related to the difference in blood pressure.

**Acknowledgments**

The authors would like to acknowledge the help of D.N. Kalkman for her valuable comments on a previous version of this article. The ACCORD (Action to Control Cardiovascular Risk in Diabetes) investigators and the National Heart, Lung, and Blood Institute (NHBII) investigators are acknowledged for conducting the trials and making the dataset available.

**Sources of Funding**

The National Heart, Lung, and Blood Institute sponsored the ACCORD trial (Action to Control Cardiovascular Risk in Diabetes). The authors did not receive any funding for conducting this post hoc analysis.

**Disclosures**

None.

**References**


What Is New?

- An initial increase in serum creatinine by >30% during antihypertensive therapy is associated with adverse clinical outcomes, irrespective of whether standard or intensive therapy is used.

What Is Relevant?

- Acute lowering of blood pressure has been shown to increase creatinine and may lead to concerns of iatrogenic kidney damage.
- Our data suggest that an initial serum creatinine increase after better blood pressure control may not always be indicative that reduction of blood pressure lowering medication is necessary.

Summary

This post hoc analysis of the ACCORD-BP trial (Action to Control Cardiovascular Risk in Diabetes Blood Pressure) shows that when stratified to serum creatinine increase intensive antihypertensive treatment does not lead to a higher risk of adverse clinical outcomes compared with standard therapy in patients with type 2 diabetes mellitus.